Role of the Arachidonic Acid Metabolites, Thromboxane A2 and Prostacyclin, in Shock Induced by Intraabdominal Sepsis by Butler, Robert Raymond
Medical University of South Carolina 
MEDICA 
MUSC Theses and Dissertations 
1981 
Role of the Arachidonic Acid Metabolites, Thromboxane A2 and 
Prostacyclin, in Shock Induced by Intraabdominal Sepsis 
Robert Raymond Butler 
Medical University of South Carolina 
Follow this and additional works at: https://medica-musc.researchcommons.org/theses 
Recommended Citation 
Butler, Robert Raymond, "Role of the Arachidonic Acid Metabolites, Thromboxane A2 and Prostacyclin, in 
Shock Induced by Intraabdominal Sepsis" (1981). MUSC Theses and Dissertations. 200. 
https://medica-musc.researchcommons.org/theses/200 
This Dissertation is brought to you for free and open access by MEDICA. It has been accepted for inclusion in 
MUSC Theses and Dissertations by an authorized administrator of MEDICA. For more information, please contact 
medica@musc.edu. 




IN SHOCK INDUCED BY INTRAABDOMINAL SEPSIS. 
by 
Robert Raymond Butler Jr. 
A dissertation submitted to the faculty of 
,the Medical University of South Carolina in 
partial fulfillment of the requirements for 
the degree of Doctor of Philosophy in the 
College of Graduate Studies. 
Department of Physiology 
1981 
APPROVED BY: 
Chairman, Advisory Committee 
Robert Raymond Butler Jr. The Role of the Arachidonic 
Acid Metabolites, Thromboxane A2 and Prostacyclin, in Shock 
Induced by Intraabdominal Sepsis (Under the direction of W. 
Curtis Wise). 
A rat fecal peritonitis model of acute intraabdominal 
sepsis was investigated in order to evaluate the potential 
role of arachidonic acid metabolites in septic shock. 
Immunoreactive (i) Thromboxane (Tx) 8 2 , the stable 
metabolite of TXA2' and i6-keto-PGF 1a , the stable 
metabolite of prostacyclin, were measured by 
radioimmuonassay. plasma levels of iTXB2 rapidly increased 
from non-detectable (ND<200 pg/ml) to 1,066 + 194 pg/ml 
(N=14) 1 hour after feces injection. 
to 1,695 + 218 pg/ml (N=16) at 4 
iTXB2 then increased 
hours and remained 
unchanged through 6 hours. plasma i6-keto-PGF1a increased 
from ND to 3,777 ± 414 pg/ml (N=16) at 1 hour. Four hours 
after feces, i6-keto-PGF1a levels rose to 6,945 t 732 pg/ml 
(N=16) then continued to rise to 9,465 t 792 pg/ml (N=7) at 
6 hours. Either essential fatty acid deficiency 
(arachidonic acid depletion) or indomethacin pretreatment 
(cyclooxygenase inhibition) significantly decreased (P(0.01) 
the elevations of plasma iTXB 2 and i6-keto-PGFla associated 
with fecal peritonitis. Thrombocytopenia occurred within 6 
Al 
hours after injection of feces and was significantly 
improved (P<0.05) by indomethacin. Elevated fibrin 
degradation products at 6 hours (18 + 3 ~g/ml) were 
significantly reduced in essential fatty acid deficient (7 t 
2 119/ml; P<0.05) and indomethacin treated (4 "! 0.7 llg/ml; 
P<0.01) rats. Survival time (8.6 + 0.2 hours) was 
significantly enhanced by essential fatty acid deficiency 
(10.2 t 0.4 hrs; P<0.01) or indomethacin pretreatment (13.3 
+ 0.6 h r s· , P<0.(1). These studies show that fecal 
peritonitis is associated with increased synthesis of 
thromboxane A2 and prostacyclin and suggest that these 
arachidonic acid metabolites may playa role in the 
pathophysiology of septic shock. 
To evaluate the pathogenic role of thrornboxane (Tx) and 
prostacyclin (PGI 2 ) in septic shock, the protective efficacy 
of the Tx synthetase inhibitor, 7(1-imidazolyl) heptanoic 
acid (7-IHA) and the cyclooxygeoase inhibitor, ibuprofen, 
were assessed during fecal peritonitis in the rat. 7-IHA 
(60 mg/kg) administered ip 30 minutes prior to feces 
significantly reduced the plasma level of iTXB2 to ND 
(P<0.01) at 1 hour and to 508 + 56 pg/ml (P<0.01) at 4 
hours after injection of feces. I n contrast, the levels of 
i 6 - k e t 0 - P G F la , the 5 tab 1 e met abo 1 i teo f P G I 2 w ere 
significantly elevated by 7-IHA pretreatment from septic 
control levels to 5,185 + 467 pg/ml (P<0.05) at 1 hour. 
Plasma i6-keto-PGF1a at 4 hours in 7-IHA treated rats 
A2 
(5,503 t 665 pg/ml) was not different from untreated 
controls. Ibuprofen (5 mg/kg) administered ip 30 minutes 
pri~r to feces significantly decreased both iTXB2 and i6-
keto-PGFla. plasma levels to 729 !* 99 pg/ml and 1,327 + 251 
pg/rnl, respectively (P<0.05) at 4 hours. Survival 
associated with fecal peritonitis was not altered by 7-IHA 
pretreatment, but was significantly improved (P<~.05) in 
ibuprofen treated rats. Fibrin degradation products were 
also significantly decreased (P<0.05) by 7-IHA pretreatment. 
These results suggest that TXA 2 may contribute to the 
coagulopathies seen in septic shock and that PGI2 may be 
associated with the terminal pathophysiologic events. 
The final phase of this project investigated the 
possible synergistic benefit between an antibiotic, 
gentamicin (GENT), and reduction of arachidonic acid 
metabolism by pre-administration of indomethacin (INDO) or 
essential fatty acid (EFA) deficiency. GENT significantly 
inc rea sed mea n sur v i val tim e to 2 3 .8 + 2 .6 h 0 U r 5 (N = 1 6 ; 
P<0.0l). GENT + INDO or GENT + EFA deficiency further 
improved mean survival time and produced long term survivals 
(>48 hrs) of 35% (N=17) and 30% (N=7) respectively (P<0.01 
compared to GENT). GENT pretreatment did not significantly 
alter plasma iTXB 2 levels, however, it selectively decreased 
i6-keto-PGF1a • For example, i6-keto-PGF lct decreased from 
9,465 ~ 792 pg/ml (N=7) to 2,096 ~ 1174 pg/ml (N=5; P<0.01) 
at 6 hours after induction of fecal peritonnitis. GENT + 
A 3 
INDO pretreatment significantly decreased both iTXB2 and i6-
keto-PGFla to ND (P<0.0l). Pretreatment with GENT alone did 
not reduce fibrin degradation products. These findings are 
consistent with the concept that TXA 2 may playa role in 
consumptive coagulopathies and PGI2 may be associated with 
the terminal hypotension seen during septic shock. 
The effect of GENT on TXA2 and PGI 2 production was 
investigated further. GENT had no observable effect on in 
vitro endotoxin stimulated production of these arachidonic 
acid metabolites by cultured rat peritoneal macrophages. 
GENT significantly reduced the plasma levels of iTXB2 and 
i6-keto-PGF1a during endotoxin induced shock in rats. These 
observations support a complex interaction of bacteria, 
endotoxin, host tissues, and gentamicin with the possible 
involvement of undescribed mediating factors. 
A4 
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Circulatory shock remains ill defined despite centuries 
of observation and experimentation. What has emerged over 
the years is the understanding that a knowledge of the 
pathophysiology of shock is relevant to all seriously ill 
patients. These two statements underscore the complexity of 
the shock syndrome and the importance of unraveling its 
mysteries. 
Historical Background 
The concept of shock as a clinical state was described 
in literature as early as William Clowes in 1568 (Seabrook, 
1881) and Ambroise Pare in 1664 (Gill, 1972); however, the 
term "shock" has been attributed to James Latta in 1795 
(Gill, 1972). Samuel Gross's (1872) classical definition of 
shock as "a manifestation of the rude unhinging of the 
machinery of life" is characteristic of this era of shock 
research. Gunshot wounds causing traumatic shock, 
hemorrhagic shock, often exacerbated by blood-letting 
therapy, and surgically induced shock were the major 
concerns through the early 19th century. The association of 
infection with shock has been attributed to Laennac in 1831 
(Shine, 1980) at a time when the microbes usually associated 
with septicemia had not been identified and classified. 
Throughout this period the descriptive symptomology remained 
1 
essentially unchanged and included pallor, feeble pulse, 
prostration, cold and clammy skin, sweating, shrunken and 
contracted features, reduced body temperature, and panting 
and sighing respiration (Dennis, 1895; Gill, 1972). The 
favored etiology of shock during this era was that it 
resulted from "a disturbance or paralysis of nerve-centers" 
(Dennis, 1895). 
At the beginning of the 20th century, prior to World 
Ttlar I, several theories of shock were proposed. According 
to Fraser (1924), four of these theories that held major 
attention were: 
1. The theory of exhaustion of the vasomotor center, 
proposed by Ceile and Mummery who felt that excessive 
vasopressor stilnuli could result in paralysis of 
vasomotor control. 
2. The acapnia theory of Henderson who said that painful 
stimuli caused hyperventilation, acapnia and venous 
stagnation, diminished venous return and led to 
hypotension. 
3. The Boise theory, that cardiac failure was the primary 
fault in "true surgical shock". 
4. The Metzler theory based on inhibition of spinal cord and 
medullary center function as a result of stimulus from 
the injury. 
By 1917, the high mortality rate from shock during 
World War I provided the incentive for an intensive study of 
the problem. The results of the studies formed the 
2 
foundation for our current undestanding of circulatory 
shock. The work of Cannon, Fraser, and Cowell in 1918 
effectively disproved the previous theories (Cannon, 19l8). 
In his 1924 publication Fraser arranged the disturbances of 
shock into four groups: 1) circulatory; 2) respiratory; 3) 
motor; and 4} sensory {Fraser, 1924}. The general 
conclusions of this work agree remarkably with our current 
concept of the shock state. 
"With the establishment of a persistently low 
blood pressure something of the nature of a 
vicious circle comes into play, the prolonged 
hypotension leads to imperfect oxygenation of the 
body tissue, and to a capillary stasis; the 
capillary stasis reduces the amount of blood in 
active Circulation, and the imperfect oxygenation 
of the tissues results in the formation of various 
toxic products from imperfect tissue metabolism" 
(Fraser, 1924). 
The only alteration necessary to make this passage entirely 
compatible with contempory views is based on findings such 
as Blalock's 1927 observations that blood pressure is an 
inadequate guide to the state of circulation during shock. 
The formation of "toxic products", however, is a persistent 
suggestion throughout the history of shock research into the 
present. The concept of such humoral mediation is 
attractive because it offers the possibility of a unifying 
mechanism against which treatment might be directed. 
Although no single factor has been described as a causative 
agent, a number of humoral agents have been identified as 
contributing to the pathogenesis of shock. Some of these 
will be discussed in a later section of this chapter. 
3 
The remainder of the 20th century was characterized by 
tremendous technical and technological expansion in the 
field of shock research, for example, the clinical 
application by Cournand et al (1943) of cardiac 
catheterization. These advances allowed detailed 
measurement of hemodynamic, metabolic and respiratory 
parameters. The correlation of these factors with 
etiologies has resulted in the categorization of numerous 
forms of shock, each form having individual features. 
However, the basic underlying principle remains as 
inadequate tissue perfusion, regardless of etiology or 
category of shock. 
Forms of Circulatory Shock 
The current "textbook definition'· of circulatory shock 
is a "generalized inadequacy of blood flow through the body, 
to the extent that the tissues are damaged because of too 
little flow, especially too little delivery of oxygen to the 
tissue cells" (Guyton, 1981). Shock is often divided into 
three stages: 1) a non-progressive or compensated stage; 2) 
a progressive stage; and 3) an irreversible or refractory 
stage. Each stage is associated with a greater perfusion 
deficiency. It is important to consider that loss of 
adequate perfusion can also be the result of deficiency in 
the quality of blood or a generalized inability of the 
tissue cells to utilize oxygen and other metabolic materials 
(Herman, 1972). The essential point is that shock is not a 
4 
disease in itself, but rather a common result of various 
primary disorders. The large number of these pr imary 
disorders is compounded by many possible combinations of 
multiple disorders making shock a vast clinical field. 
pragmatic classifications have evolved that are designed to 
ascribe different mechanisms based on etiology. These 
classifications include hypovolemic, cardiogenic, septic, 
anaphylactic, neurogenic, obstructive, traumatic, 
hemmorrhagic, and endocrine, all common terms in the field 
of shock research. The three most common etiologic forms of 
shock are hypovolemic, cardiogenic, and septic (Ledingham, 
1979). Table I shows the differences in hemodynamic 
alterations observed in these three types of shock. From 
these observations it is apparent that the underlying 
mechanisms and alterations must be considered individually. 
A more descriptive classification that is useful in 
identifying both cause and therapy has been suggested by 
Weil, et al (1972). This system includes four basic types 
of shock; 1) hypovolemic, with either exogenous or 
endogenous blood loss; 2) cardiogenic; 3) obstructive; and 
4) distributive, having either high or normal resistance 
with increased venous capacitance, or low resistance with 
arteriovenous shunting. These four categories encompass all 
of the previously defined etiologic categories according to 
the current understanding of the mechanisms involved. 
The present study dealt with shock produced by 
intraabdominal sepsis in rats. This is one of the models 
5 
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used to investigate the pathophysiology of septic shock. 
Before describing the current concepts of this 
p~thophysiology it is important to consider the different 
model systems that have been employed in gathering the 
information used to support these concepts. 
Model Systems in the Study of Septic Shock 
Direct clinical observation of patients with septicemia 
has been a major source of data used in the formulation of 
our present understanding of septic shock. The large number 
of variables in the clinical setting however, makes it 
difficult to perform controlled studies. For this reason, 
animal models have been used to gather data. As an 
example" the hemodynamic alterations of septic shock shown 
in Table I are quite variable. This variability stems in 
part from the number of possible infecting organisms and 
sites of infection. Both Gram-positive and Gram-negative 
bacteria as well as fungi, viruses, and spirochetes can 
cause shock (Wardle, 1979). Gram-negative sepsis is most 
often associated with septic shock because the cell wall of 
these organisms contains lipopolysaccharide, also known as 
endotoxin. Endotoxin administration produces activation of 
clotting via Hageman factor, disseminated intravascular 
coagulation, hypotension, altered leukocyte levels, 
activation of fibrinolysis, activation of complement, 
platelet release of vasoactive and coagulation promoting 
substances, endothelial damage and release of leukocyte 
6 
effector substances (Shine, 1980). Since these are similar 
to the pathophysiologic events associated with septic shock, 
endotoxic shock has been used extensively as a model for 
se"ptic shock. As a consequence many of the alterations of 
function ascribed to septic shock in the literature have 
been evaluated in endotoxic shock. This practice of using 
the terms septic and endotoxic shock synonymously has been 
criticized. The response to endotoxin administration is 
different from the response to Gram-negative sepsis in terms 
of physiological response, including leukocyte count, 
peripheral resistance, cardiac output, and carbohydrate 
metabolism (Waisbren, 1964; Wichterman, 1980). Many studies 
have failed to show a correlation of shock and fatality to 
circulating endotoxin levels during gram-negative bacteremia 
(Greisman, 1969; MeG ill, 1970; Martinez, 1973; Young, 1977; 
Yates, 1980). In addition, despite several attempts it is 
still doubtful whether a reliable method exists that can 
distinguish between endotoxin producing Gram-negative 
septicemia and Gram-positive septicemia where no 
lipopolysaccharide endotoxin is present (Winslow, 1973; 
Wardle, 1979; Shine, 1980). These observations do not argue 
against the involvement of endotoxin in septic shock nor 
lessen the importance of studies using this model. However, 
they do suggest that equating endotoxic and septic shock is 
unwarranted at the present time. 
Another approach to the study of septic shock is to 
produce sepsis in laboratory animals. This has been 
7 
accomplished by intravenous infusion of live organisms, 
placement of infected foreign material into soft tissues and 
surgical disruption of the normal barriers of the 
gastrointestinal tract. These procedures have been reviewed 
recently by Wichterman, et al (1980). As with any model 
system each of these methods has advantages and 
disadvantages and the clinical relevance of the results must 
be considered with healthy skepticism. Towards this end, 
Wichterman et al (1980) have proposed guidelines for 
progressive and lethal sepsis models. These guidelines 
briefly consist of the following: 
1. Positive blood cultures 
2. Clinical symptomology 
3. Appropriate time period 
4. Reproducibility 
5. Defined serum glucose, serum lactate and cardiac 
output if possible. 
The fecal peritonitis model used in the present study 
meets these guidelines. Using this model system Yates et al 
(1980) measured the plasma glucose, plasma lactate and 
arterial blood pressure (cardiac output was not measured) 
and reported alterations that correspond to other studies of 
septic shock (Postel et al., 1977a; Wichterman et al., 1977; 
Hardaway et al., 1981). positive blood cultures, clinical 
symptomo!ogy, internal reproduciblity and an appropriate 
survival time that corresponds to the Yates study were 
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obtained in the present study and are discussed in the 
Methods section of Chapter II. This model system, then, 
should be appropriate for investigating the pathophysiology 
of 'septic shock. 
pathophysiology of Septic Shock 
The incidence of Gram-negative bacteremia increased 
almost 20 fold in the 20 years preceding 1974 (McCabe, 
1974). Several factors may be contributing to the rapidly 
increased frequency of this disease. The increased use of 
immunosuppressive drugs enhance susceptibility to infection. 
severely injured patients, transplant patients, cancer 
patients, diabetes patients, etc. are surviving longer with 
an increased risk of infection. Increased use of devices 
such as indwelling intravenous catheters for 
hyperalimentation and bladder catheters increased the 
potential for infection. A major concern is that bacteremic 
shock still has a mortality rate of over 50 percent (Wardle, 
1979). Therapy can not yet be planned to deal with the 
complex pathophysiological processes of this syndrome 
because many of the underlying mechanisms are not 
understood. As previously stated, the underlying principle 
is inadequate tissue perfusion in all forms of shock. The 
present study is concerned with how sepsis, an acute 
condition wherein an animal is toxic because of invasive 




Invasive bacterial infection results in stimulation of 
the immune system of the host. Lymphocytes, mast cells, 
macrophages and other cells of the immune system respond to 
the stimulation by releasing potent vasoactive substances 
such as br-adykinin, histamine, prostaglandins and 
catecholamines. These substances activate receptors of the 
microcirculation and also produce peripheral and central 
sympathetic nerve activity which results in the release of 
serotonin, epinephrine and norepinephrine from autonomic 
nerve terminals and the adrenal medulla. The more immediate 
effect is a transient peripheral vasodilation that manifests 
itself in a state known as "warm shock". As tissue injury 
continues there is an intense constriction of vessels of the 
pulmonary, renal, splanchnic and peripheral vascular beds. 
This constriction preserves the coronary and cerebral blood 
flow at the expense of flow to other organ systems (Lillehei 
et al., 1967; Freid et al., 1968; Barnett et al., 1969; 
Christy, 1971; Lees et al., 1976; Duff, 1980). 
In addition, the multiple afferent stimuli associated 
with sepsis (e.g., altered blood volume, pH and osmolarity, 
hypoxia, tissue damage, pyrogens and toxins) are integrated 
in the hypothalamus and relayed to the sympathetic nervous 
system, the adrenal medulla, and the pituitary which 
initiate neuro-hormonal responses. The basic endocrine 
activation in shock involves release of catecholamines, 
angiotensin, cortisol, growth hormone, glucagon, 
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antidiuretic hormone and aldosterone. The combined effect 
is to mobilize energy reserves and conserve salt and water. 
These mechanisms are generally protective in the short term, 
but sustained activation leads to the breakdown of cellular 
integ r i ty (Led ingham, 1979). 
Humoral Agents 
Thus, there are a variety of inflammatory and hormonal 
systems contributing to the early phase of septic shock. It 
is important to consider the known actions of the more 
prominent vasoactive substances that are released. There is 
a massive outpouring of catecholarnines in all forms of shock 
and high catecholamine levels appear to be associated with a 
poor prognosis (Ledingham, 1979). Angiotensin II is also 
released in the blood following shock. Catecholamines and 
angiotensin II stimulate secretion of one another and 
therefore have an additive vasoconstrictor effect. 
Histamine has loog been thought to have a role in the 
etiology of shock and its presence in the blood of septic 
patients has been demonstrated. It is derived partly from 
mast cell granules and is a systemic vasodilator (Ledingham, 
1979). However, 
and has been 
in the lung histamine is a vasoconstrictor 
shown to increase pulmonary capillary 
permeability, lymph flow, and pulmonary extravascular water 
content (Beyer, 1979). 
plasma kinins are vasodilator polypeptides which also 
increase capillary permeability. Their activation from 
11 
precursors in the alpha2-g1obulin fraction of plasma protein 
has been associaLed WiLh Lhe early phases of septic shock 
(Robinson, 1975). A fall in kinin levels has been observed 
following relief of sepsis with a concomitant resolution of 
hemodynamic disturbances (O'Donnell et al., 1976). The 
initiating factor appears to be activation of Hageman factor 
which leads to the production of kinin by the proteolytic 
enzyme, kallikrein, which is released from leukocytes and 
injured tissue. Activation of Hageman factor also promotes 
complement activation. Massive intravascular complement 
activation is associated with the later stages of septic 
shock (Sheagren, 1981). A complex series of events that 
accompanies complement activation, centered around C 3 and C 
5 components, has been described by Jacob et ale (1980). 
These peptides produce vasodilation and activation of 
granulocytes. Activated granulocytes tend to aggregate and 
adhere to vascular endothelium causing release of 
arachidonic acid derivatives (Weksler, 1980), cytotoxic 
products of molecular oxygen (Jacobs, 1980), and lysosomal 
enzymes (t-.[eissmann, 1980). The result is increased 
vasoactivity in the microvasculature and endothelial cell 
cytotoxicity and capillary leakage. 
Endorphins and arachidonic acid metabolites are among 
the more recently studied substances that have been 
implicated in septic shock. Endorphins produce significant 
hypotension at a fraction of the dose required for 
analgesia. This effect appears to be mediated by opiate 
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receptors within the central nervous system (Faden, 1980). 
Arachidonic acid metabolites are synthesized by many cells 
inc.luding activated granulocytes, macrophages, endothelial 
cells and also by blood platelets. They have a wide range 
of effects on the cardiovascular systelu. Since the role of 
these products in septic shock was the subject of this study 
they will be considered in detail in the next section of 
this chapter. 
Microvascular Response 
At present, it is not possible to predict the effects 
on the microcirculation of the combined release of the above 
hurnocal agents. It is clear, however, that a massive 
release of such potent vasoactive products must have 
important consequences in shock states. The ultimate 
response of individual patients or experimental animals is 
dependent on the relative production versus potency of each 
agent in the blood and tissues. Early in the constrictive 
phase of shock, both arterioles and venules are constricted 
producing ischemic anoxia in the microcirculation of the 
viscera (lung, skin, etc.). With sepsis or some other 
severe shock producing insults, there is a transition from 
ischemic anoxia to stagnant anoxia. In stagnant anoxia 
arteriolar constriction is diminished while venular 
constriction remains resulting in stagnation and pooling 
with an increased hydrostatic pressuce in the capillary 
c i rculat ion. A proposed explanation for this transition is 
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that the venular side of the circulation is normally exposed 
to lower oxygen tension and a more acid pH and therefore 
maintains tone longer than the arteriolar side (Lillehei, 
197"2a). Another event associated with the stagnant- anoxia 
is aggregation of cellular components and the possiblity of 
disseminated intravascular coagulation (DIe). Anoxic injury 
to the vascular endothelium along with sludging of the blood 
is a major stimulus for activation of the coagulation 
cascade. These factors combine with infection-induced toxic 
products that have thromboplastin-like activity to trigger 
the catastrophic events of DIe (Duff, 1980). In addition to 
compounding the perfusion problem, DIC results in 
consumption of clotting elements and can lead to hemorrhagic 
complications. DIC is more often a late complication of 
septic than other forms of shock. 
Generally the clinical signs of septic shock in man are 
similar to those found in other types of shock: cold, pale, 
or cyanotic extremities, hypotension, and oliguria or 
anuria. The principal difference between septic and other 
forms of shock is an accelerated deterioration of the 
microcirculation in septic shock that is presumably caused 
by exposure to endotoxin (Lillehei, 1972a). But there is 
another important difference between clinical septic shock 
and other etiologic forms of shock or experimental endotoxin 
shock that must be considered. This is the normal or high 
cardiac output and normal or low total peripheral resistance 
usually encountered in patients with septic shock. In 
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hypovolemic, cardiogenic and experimental endotoxic shock 
cardiac output is reduced and total peripheral resistance is 
high; in contrast, if the heart previously has been normal, 
the cardiac output falls very late in septic shock. The 
explanation for this discrepancy appears to reside in the 
microvasculature. Observations of arteriovenous oxygen 
differences and oxygen uptake suggest that shunting occurs 
in septic shock (Lillehei, 1972). This shunting would 
enhance oxygen deprivation in the tissue cells and provide a 
reduced total peripheral resistance. Maldistribution of 
tissue perfusion is an ill defined aspect of shock, but it 
is known that even when overall flow to an area seems 
adequate, the flow may be traversing "preferred" route 
capillaries rather than "nutrient" vessels and shunting 
through arteriovenous anastomoses may also occur (Silver, 
1977) • 
The question remains as to why this type of 
microvascular shunting appears in septic and not other forms 
of shock. The answer rnay reside in the inflammatory 
response induced by bacteria. The inflammatory aspect of 
infection and its relation to arteriovenous shunting in the 
microcirculation was noted by Metchnikoff as early as the 
1890's (Lillehei, 1972). Injection of living bacteria into 
experimental animals similar to the injection of endotoxin, 
will not produce the high-output low-resistance form of 
septic shock unless a focus of inflammation has also been 
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produced (Hermrec, 1969; Motsay, 1971). The classification 
system of Weil et ale (1972) includes four forms of 
circulatory shock - hypovolemic, cardiogenic, obstructive, 
and distributive (see Forms of Circulatory Shock in this 
chapter) • In this classification, septic shock is 
considered to be a distributive defect with two major 
subg ["oups. One group has high peripheral resistance with 
intravascular sequestration of blood. This produces a 
"relative hypovolemia" since the total intravascular fluid 
volume is near normal but the capaci.ty of the intravascular 
fluid space is greatly expanded. The other group has low 
peripheral resistance and blood is either shunted from 
arterial to venous circulation or traverses capillaries 
without effective exchange of oxygen at the cellular level. 
Fur the r (0 0 r e , the sea u tho r s h a vee 0 r r e 1 ate d the h i 9 h 
resistance defect to bacteremia whereas the low resistance 
defect has been correlated with peritonitis and multiple 
infections (Weil et al., 1979). 
Further investigation is required before an exact 
explanation of this process is possible. Many of the 
vasoactive substances associated with shock, such as 
arachidonic acid metabolites, may be involved in the 
initiation of this local arteriovenous admixture. I n any 
event the effect on tissue anoxia from such a shunting in 
septic shock is readily apparent. Stagnant anoxia produces 
a significant drop in nutritional blood flow to the tissues. 
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Arteriovenous shunting compounds this insult by diverting 
nutritional blood flow away from or around these stagnant 
bed.s. This two fold basis for anoxia may be responsible for 
the suddenness of shock in sepsis and the profound 
deterioration of hepatic, renal, and pulmonary function. 
Metabolic Alterations 
The diminished effective blood flow in these various 
organ systems results in the development of tissue hypoxia. 
Decreased tissue oxygen levels cause cellular energy 
production to convert from aerobic to anaerobic metabolism. 
In addition to decreased flow, transfer of oxygen to the 





by changes in tissue 
1979). Altered pH, 
oxygen 
pC0 2 , 
temperature, and 2,3-diphosphoglycerate levels influence the 
dissociation curve while increased tissue oxygen consumption 
is a product of sepsis. The increased use of anaerobic 
metabolic pathways leads to the production of lactic acid. 
Daniel et al. (1976) have suggested that increased lactate 
production results from increased metabolism of 
carbohydrates and certain amino acids and a decrease in 
metabolism of free fatty acids. Other work using a septic 
model (Burns et al., 1978) has suggested an inhibition of 




of tissue metabolism 
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membranes. These 
result in local and 
eventually systemic acidosis which prompts further release 
of vasoactive substances (peterdarf, 1970; Duff, 1980). 
Hypoxia and acidosis are thought to cause the change in 
Inicrocirculatory hemodynamics described above. This shift 
from ischemic anoxia to stagnant anoxia is associated with 
significant pooling of blood in capillary beds and creates a 
relative hypovolemia. Increased hydrostatic pressure in 
these capillary beds leads to transudation of fluid into the 
interstitium. This is referred to as "third space loss" and 
is particularly harmful in the lung (Gill et al., 1972; 
Lillehei et al., 1972a; Duff, 1980). It is possible for the 
loss of intravascular fluid to reach proportions that 
compromise cardiac output and blood pressure. Reduced 
systemic arterial pressure results in activation of the 
baroreceptor reflex and further sympathetic vasoconstrictor 
input. Also, increased blood viscosity is associated with 
this aspect of septic shock. Red cell and platelet 
aggregation compromise flow in the microvasculature further 
reducing tissue perfusion (Ledingham, 1979). 
Ultracellular Alterations 
At the ultracellular level cells swell, lysosomes 
rupture and cells begin to autolyze as a result of tissue 
anoxia (Duff, 1980). The combination of reduced ATP 
formation and acidosis impairs cellular function and, in 
particular, the sodium pump mechanism, leading ultimately to 
an increase in intracellular water (Ledingham, 1979). The 
major source of lysosomal enzymes appears to be the 
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splanchnic organs, particularly the liver and pancreas. The 
changes in lysosomes appear to be related to the 
per~eability of the lysosomal membrane, the configuration of 
the vacuolar apparatus of lysosomes and the amount and type 
of acid hydrolase enzymes within the lysosome. Lysosomal 
disruption and subsequent release of these enzymes into the 
surrounding cytoplasm can be quite devastating to the 
structural integrity and metabolic functions of the cell 
(Lefer et al., 1977). These ultrastructural changes result 
in the production and release of toxic factors and result in 
vasomotor collapse, mental confusion, and "multiple organ 
failure". 
~ultiple Organ Failure 
In the context of multiple organ failure, the heart, 
lung, kidney, and liver are of particular importance. 
Heart: As noted above, the heart generally fails only 
during the very late stages of septic shock. However, 
several extracardiac factors have been proposed that may 
cause some impairment of myocardial function. For example, 
Lefer (1977) has postulated a myocardial depressant factor 
(MDF) that is a circulating peptide released froln hypoxic 
pancreatic acinar cells. Also in septic shock, edema of 
cardiac muscle has been observed in experimental studies 
(Postel et al., 1977). 
Lung: The syndrome of acute respiratory insufficiency 
associated with circulatory shock is often referred to as 
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shock lung or adult respiratory distress syndome (ARDS) and 
has been recently reviewed by Beyer (1979). Decreased 
pulmonary blood flow, hypoxic injury to the pulmonary 
cap ill a ry endo·thel i urn and inc ceased pe rmeabi 1 i ty of the 
microvasculature, transudation of fluid into the 
interstitium, formation of microthrolubi, bleeding into the 
lung parenchyma and destruction of surfactant combine to 
result in reduced pulmonary compliance and extensive 
atelectasis. 
Kidney: There is not always a close relationship 
between the severity of shock and incidence of acute 
intrinsic renal failure. several vasoactive substances such 
as catecholamines, angiotensin II and vasodilator 
prostaglandins appear to play interacting coles in 
controlling the ischemic condition of the kidney. Modern 
hemodialysis techniques have allowed restoration of normal 
renal function following ischemic states that were 
previously considered irreversible (Ledingham, 1979). 
Liver: Hepatic dysfunction following septic shock is 
widely recognized. Hepatic blood flow and oxygen 
consumption fall during septic shock associated with high 
resistance. Edema, swelling and vacuolization of liver cells 
have been observed during this state, and, if the condition 
persists for 24 hou["s, hepatic necrosis is conlmon. I n low 
resistance septic shock total hepatic blood flow is 
increased but not in proportion to cardiac output. The 
greatly increased oxygen demand of the liver during this 
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condition may not be met by the functional perfusion. 
Various toxic products of sepsis also contribute to liver 
da~age. In addition to the important metabolic functions, 
hepatic reticuloendothelial function may be compromised 
during septic shock (Ledingham, 1979). This is particularly 
important since the reticuloendothelial system is a major 
defense mechanism against sepsis. 
Summary 
In summary, septic shock is among the most severe 
insults that can be inflicted on the body's homeostatic 
mechanisms. The microvasculature in particular is affected 
through the release of many vasoactive substances in amounts 
not seen in healthy subjects. Damage to the microstructure 
of many susceptible tissues is often considerable and 
produces a generalized dysfunction. 
As mentioned above, arachidonic acid metabolites 
include vasoactive substances that have been implicated in 
the pathophysiology of shock. The next section will 
consider the potential involvement of these substances in 
circulatory shock. 
Arachidonic Acid Metabolites and Shock 
The observation that human seminal fluid caused 
contraction of uterine smooth muscle (Kurzrok et al., 1930) 
led to the description by Goldblatt (1933) and von Euler 
(1934) of potent smooth muscle stimulation and hypotensive 
activities of semen. These activities were shown to be due 
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to acidic lipid soluble material which was labelled 
"prostaglandin" because it was thought to come from the 
prostate gland (von Euler, 1936). The source of these 
activities is now known to be a series of cyclopentane 
derivatives formed from polyunsaturated fatty acids and, 
although prostaglandins are produced by many different 
tissues and have many physiological functions, the name has 
remained. Standard use of the term prostaglandins belies 
the complexity of the cascade of active substances that are 
produced from polyunsaturated fatty acids. These fatty 
acids are primarily dihomo-gamma-linolenic acid, arachidonic 
acid, and eicosapentaenoic acid, which give rise to mono-, 
b i s- 0 r t r i e n 0 i cpr 0 S tag 1 and ins, res pee t i vel y • The 
nomene la tu re assoc iated with prostag land ins (PG s) has been 
reviewed by Nelson (1974). Arachidonic acid is the most 
common fatty acid precursor in membrane phospholipids and 
the bisenoic prostaglandins are the principal prostaglandins 
found in biological systems and appear -to be of greatest 
biological significance (Halushka et al., 1979; Moncada et 
al., 1979). 
Prior to 1973, PGE2 and PGF 2a were chemically 
identified and considered to be the only metabolites of 
arachidonic acid with substantial biologic significance. 
However, recently there have been many discoveries 
concerning the nature of intermediates of arachidonic acid 
metabolism (Fig. 1). There are at least two types of 
enzymes involved (Moncada, 1979). Lipoxygenases peroxidize 
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Figure 1. Products of the metabolism of arachidonic acid. 
The products of major concern in this project 
were thromboxane A2 and prostacyclin (PGI 2). 
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6-keto-PGF 1 0& 
arachidonic acid forming unstable hydroperoxides which break 
down to stable hydroxyacids or are further transformed into 
pro.ducts called leukotrienes. Description of this pathway 
has opened an entirely new field of study. The second 
en z y m e i s fat t y- a c ide y c 100 x Y g en a s e , a Iso k now n as 
prostaglandin synthetase, that forms the prostaglandin 
endoperoxide PGG 2 - After conversion to another 
endoperoxide, PGH 2 , enzymatic or non-enzymatic breakdown 
results in the formation of the stable prostaglandins, PGE?, 
PGF 2a , PGD 2 , and a 17-carbon hydroxyacid (HHT) plus 
malondialdehyde (MDA). prostaglandin endoperoxides are also 
transformed by thromboxane synthetase into thromboxane (TX) 
A2 and by prostacyclin synthetase into prostacyclin (PGI 2). 
These are two unstable products that spontaneously break 
down to less active TxB2 and 6-keto-PGF 1al respectively. 
Nearly all of these products of arachidonic acid metabolism 
have potent biologic activity and this cascade of active 
substances has been shown to participate in thermal injuries 
(Sondergard et al., 1970), peptic ulcer (Wilson ~ al., 
1971), dysmenocrhea (Behrman et al.,1974) kidney disease 
(M cG iff eta 1., 197 3 ), d i a r r h e a (M a t a c han sky eta 1., 1 97 3 ) , 
platelet function (Smith ~ al., 1976), vascular dysfunction 
(Coceani et ~l., 1978), fever (Milton~.! al., 1970), 
inflammation (Arora et al., 1970) and circulatory shock 
(Collier et al., 1973). Many of these physiological 
processes are associated with shock and trauma; therefore, 
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it is probable that arachidonic acid metabolism plays an 
important role in circulatory shock. 
Non-steroidal anti-inflammatory drugs were reported by 
Nor'thover et al. (1962) to attenuate the hemodynamic events 
associated with endotoxic shock. These drugs were late~ 
shown to inhibit prostaglandin synthetase (Ferreira, 1971), 
suggesting that beneficial effects during shock may be 
mediated by the prostaglandin system. Subsequent studies 
confirmed that prostaglandins of the A, E, and F series were 
elevated during endotoxic shock (Collier et al., 1973; 
Anderson et al., 1975; Fletcher et a.!.., 1978) and that 
inhibition of their production by fatty-acid cyclooxygenase 
(prostaglandin synthetase) was beneficial in several models 
and types of circulatory shock (Fletcher et al., 1980). 
However, inhibition of fatty-acid cyclooxygenase reduces the 
production of not only the stable prostaglandins but also 
These thromboxane (TXA2) and prostacyclin (PGI 2 ). 
substances, TXA 2 and PGI 2 have been shown to be particularly 
potent as vasoconstrictor and platelet pro-aggregator and 
vasodilator and platelet anti-aggregator, respectively 
(Moncada ~ al., 1979). These actions within the vascular 
system suggested that TXA 2 and PGI 2 may be involved in the 
pathophysiologic disseminated intravascular coagulation and 
pulmonary and mesenteric vasomotor alterations associated 
with endotoxic shock. In support of this concept, TXB2' the 
stable metabolite of TXA 2 , has been shown to be elevated 
during endotoxic shock (Cook et a1., 1980) and myocardial 
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ischemia (Smith et al., 1979). Also 6-keto-PGF 1a , the 
stable metabolites of PGI 2 , was shown to be elevated during 
endotoxic shock (Bult et al., 1978). 
These previous studies thus implicate the arachidonic 
acid metabolites, TXA2 and PGI 2 , in the pathophysiology of 
shock using primarily an endotoxic shock model~ Very few 
studies have been performed concerning arachidonic acid 
metabolism using a sepsis model and there are no reports 
concerning thromboxane or prostacyclin production during 
septic shock. Therefore, the objective of the present study 
was to investigate the role of thromboxane and prostacyclin 
production during septic shock using a fecal peritonitis 
model of intraabdominal sepsis. 
Specific Aims 
The hypothesis to be tested was that the arachidonic 
acid metabolites TXA2 and PGI 2 are functionally involved in 
the pathophys io logy of c i rcula to ry shock induced by septic 
peritonitis. previous findings have cast TXA 2 in a 
deleterious role and PGI2 in a beneficial role during 
endotoxic, hemorrhagic and traumatic shock. Compatible 
results would be expected in a septic shock model. The 
project was organized into the following phases: 
1) Thromboxane and Erostacyclin production durin~ 
seEtic shock. The initial objective was to describe the 
time course of the production of TXA2 and PGI 2 during fecal 
peritonitis using radioimmunoassay of their stable 
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metabolites TXB 2 and 6-keto-PGF1 Ct.I respectively. Control 
untreated rats and two experimental groups, essential fatty 
acid deficient and indomethacin pretreated rats, were 
observed. In addition to plasma levels of the above 
metabolites, survival time, platelet counts, and fibrin 
degradation products were measured in each group. These 
experiments were designed not only to determine the rate of 
production of TXA 2 and PGI2 during shock, but also to 
evaluate the potentially protective efficacy of reduced 
arachidonic acid metabolism in ter-ms of survival and 
consumptive coagulopathies. 
2 ) Studies on the role of thromboxane and 
prostacyclin during shock induced £y intr-aperitoneal sepsis. 
The second objective was to further define the roles of TXA2 
and PGI 2 by using the specific thromboxane synthetase 
inhibitor 7-(1-imidazolyl) heptanoic acid (7-IHA). Control 
untreated, 7-IHA treated and ibuprofen ( a cyclooxygenase 
inhibitor) treated rats and rats with non-septic peritonitis 
produced by injection of sterile fecal suspension were 
o bse rved. The same parameters were measured as in the 
initial phase. The alteration of PGI 2 production was 
analyzed and correlated with the other results. 
3). synergism between gentamicin and indomethacin or 
essential fatty acid deficiency in the treatment of septic 
shock: Effects on the .E.!..oduction oi thromboxane A2 and 
pro s t a.£Y c 1. in. The final objective was to exarnine the 
therapeutic efficacy of reduction of arachidonic acid 
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metabolism as an adjunct to the single most effective 
treatment currently in 
administration. Essential 
use, namely, antibiotic 
fatty acid deficiency and 
indomethacin pretreatment were again used, this time in 
con j u net ion wit h 9 e n t a in i c i n pre t rea t men t • Mea sur e d 
parameters were the same (survival time, TXB 2 and 6-keto-
PGFl a plasma levels, platelet counts, and fibrin degradation 
pcoduc ts). The e f fec t 0 f gen tam i c in t rea tmen t on TXA 2 and 
PGI2 production was also analyzed. 
Using these techniques, the production of TXA 2 and PGI 2 
was correlated to the septic shock response beginning with 
the measurement of baseline levels and ending with the 
description of a highly effective, synergistic treatment 




THRormOXANE AND PROSTACYCLIN PRODUCTION 
DURING SEPTIC SHOCK 
INTRODUCTION 
Thromboxane A2 (TXA 2 ) and prostacyclin (PGI 2 ) are two 
vasoactive metabolites of arachidonic acid that have been 
implicated in the pathophysiology of circulatory shock. 
TXA 2 is a potent vasoconstrictor and platelet aggregator 
while PGI 2 is a potent vasaodilator and platelet anti-
aggregator (Moncada et al., 1979). This combination of 
biologic activities has suggested a possible role for these 
substances in the pulmonary hypertension, systemic 
hypotension, and disseminated intravascular coagulation 
characteristically associated with shock. In support of 
this concept, inhibitors of the enzyme fatty acid 
cyclooxygenase decrease the metabolism of arachidonic acid 
and have been shown to afford protection against the 
pathophysiologic sequelae of hemorrhagic (Lefer et al., 
1978 ), end 0 to x i c (C 0 0 k e t a~., 198 0 ; W i s e eta 1. , 198 0 ; 
Halushka et ~l., 1981), and septic shock (Short et al., 
1981). Furthermore, plasma levels of TXA 2 and PGI 2 
metabolites have been shown to be elevated in endotoxic 
shock (Cook et al., 1980; Harris et al., 1980; Halushka et 
al., 1981). In this regard, TXA2 is felt to be deleterious 
whereas PGI 2 is considered as beneficial (Lefer, 1979; Cook 
et al., 1980; Lefer et al., 1980; Demling et al., 1981; Wise 
et al., 1981). 
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previous studies evaluating the production of TXA2 and 
PGI 2 during endotoxemia have utilized a single bolus 
in~ravenous injection of endotoxin. While this has produced 
dramatic elevations in plasma levels of arachidonic acid 
metabolites, it has raised the question if a sustained 
insult with a slowly increasing magnitude, such as that seen 
in fecal peritonitis, may also be associated with a similar 
increase in release of these products. In this phase of the 
project a fecal peritonitis model of acute intraabdominal 
sepsis was investigated in order to: 1) measure alterations 
in plasma levels of iTXB2 (the stable metabolite of TXA 2 ) 
and i6-keto-PGFla (the stable metabolite of PGI 2 )i and 2) 
evaluate the potential role of these metaboites in septic 
shock. The following parameters were measured in rats 
challenged with intraperitoneal injections of fecal 
suspension: 1) plasma iTXB 2 level Si 2) plasma i6-keto-PGF kt 
levels; 3) severity of thrombocytopenia; 4) fibrin 
degradation products (FDP); and 5) survival time. This 
study also included investigation of the effects of 
essential fatty acid (EFA) deficiency and indomethacin 
(INDO) treatment on these parameters. 
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MATERIALS AND METHODS 
Female Long-Evans rats, 200-250 9 (17-19 weeks old), 
used for these experiments, came from a breeding colony 
maintained by Dr. W.C. Wise at the Medical University of 
South Carolina. The rats were allowed ad libitum access to 
food and water. Food was obtained from Wayne Food (Allied 
Mills, Inc., Libertyville, IL) and contained a minimum of 
24% protein, 4.5% fiber, and 4% fat. Of the fat content 
36.66% is linoleic acid, 2.45% linolenic acid, and 4.16% 
arachidonic acid. Essential fatty acid (EFA) deficient rats 
were fed a fat free diet obtained from IeN Nutritional 
Biochemical (Cleveland, Ohio) consisting of 21% vitamin free 
casein, 16.5% alphacel, 58% sucrose, 4% salt mixture and 
vitamin supplements. The protocol for induction of EFA 
deficiency has been described by Cook et ale (1981). 
Fecal Peritonitis 
Fecal peritonitis was induced by intraperitoneal 
injection of a fecal suspension. To form the suspension, 
fecal material was collected from the colony, diluted and 
filtered through 20 gauge stainless steel mesh. The final 
dilution was adjusted to 0.05 mg/ml dry weight. Aliquots of 
the fecal suspension and blood samples collected from the 
inferior vena cava were analyzed for general aerobic and 
anaerobic microbial content. Serial dilutions were applied 
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Figure 2. Percent survival during septic shock. Fecal 
peritonitis was produced at time zero by ip 
injection of fecal suspension (0.75 mg dry wt/ 

























































to 5% sheep blood agar plates with a calibrated loop (0.001 
enl) to obtain total counts. Growth characteristics on 
va~ious media and standard biochemical taxonomic reactions 
were used to determine the predominant microorganism types. 
All rats were fasted 12 hours prior to induction of fecal 
peritonitis. Controlled dosage of the suspension was 
injected with an 18 gauge needle into rats under light ether 
anesthesia. 
To characterize the response of rats to fecal 
peritonitis various doses of the fecal suspension were 
adm ini ste red. Both mean survival time and percent survival 
(>48 hours) varied in a dose dependent manner. The standard 
dose employed in this study was 0.75 mg dry weight/kg body 
weight. This produced a mean survival time of 8.6 + 0.2 
hours (N=50) and 100% mortality within 14 hours (Fig. 2). 
Neither survival nor mortality varied with different fecal 
suspension preparations. 
Bacteriologic analysis revealed the expected large 
spectrum of aerobic and anaerobic microorganisms (e.g., E. 
coli, Pseudomonas, Bacteroides, Lactobacillus). Total count 
plates indicated 108 - 10 9 organisms per ml of suspension. 
Number and type of bacteria varied only slightly in 
different preparations of fecal suspension. Blood cultures 
revealed 3 x 10 4 organisms/ml with equal numbers of Gram-
positive and Gram-negative bacteria at 1 hour after feces 
injection. At 4 hours, approximately the same number of 
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organisms were present but all colonies were Gram-negative 
bacilli. pseudomonas putida was the only microorganism 
colony that cultured out at 4 hours. These results were 
essentially unchanged with several fecal suspension 
preparations. 
Radioimmunoassay of Immunoreactive (i) TxB2 and 6-keto-PGF1a 
After opening the abdominal cavity under ether 
anesthesia, blood was collected from the inferior vena cava 
into plastic syringes containing 0.2 rnl of indomethacin-
heparin solution (3 mg of indomethacin, 2500 U of heparin 
per ml of 0.1 M sodium-phosphate buffer, pH 8.0) for 
determination of iTxB 2 and i6-keto-PGF 1a Blood was 
centrifuged (1500 x 9 for 20 min) and the plasma was 
collected and frozen at -20 C until extraction. 
For the iTxB2 assay, [3 H ]TXB 2 (1500 cpm) was added to 
the 1 ml plasma sample to allow computation of loss during 
the extraction procedure. This plasma was acidified to pH 
3.5 with formic acid and extracted twice with 6 rol of ethyl 
acetate. The ethyl acetate layer was removed and dried 
unde r nit rogen. The dried extract was reconstituted and 
applied to a silicic acid column (0.5 g) and the TXB 2 
fraction was collected and dried under nitrogen (Burch et 
al., 1979). The dried extract was reconstituted in 0.5 ml 
of gelatin-phosphate buffered saline. iTXB 2 was determined 
using a previously described radioimmunoassay (Burch et al., 
1979). The antibody does not cross react significantly with 
other arachidonic acid metabolites and the inter-assay 
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variability was 12% (N=8). The minimum detectable amount is 
less than 200 pg/ml plasma. 
For the i6-keto-PGF1 a, assay, 0.1 rnl of unextracted 
plasma was added to 0.9 ml of gelatin-phosphate buffered 
saline. The amount of i6-keto-PGF1 ct in this diluted sample 
was determined using a previously described radioimmunoassay 
(\i i s e eta 1. , 1 9 8 0 ) • The antibody does not cross react 
significantly with any other arachidonic acid derived 
product and the interassay variability was 9.6% (N=8). The 
minimum detectable amount is less than 200 pg/ml plasma. 
Consumptive coagulopathy 
Blood platelets were counted using the method of 
Brecher and Cronkite (1950). Serial samples of blood were 
obtained from the tail vein and diluted in 1% ammonium 
oxalate (unopette, Becton-Dickinson, Orangeburg, N.Y.). The 
measurement of fibrin degradation products (FDP) in serum 
was based on the staphylococcal clumping method of Hawiger 
et ale (1970) using a commercially available kit (Sigma, 
#850) • 
Survival Time 
Determination of survival time was made by direct 
observation. Shocked rats progressed through a 
characteristic series of symptoms that included lethargy, 
reduced respiratory rate, loss of reflexes (e.g., righting 
reflex) , convulsions and cessation of respiration. 
Cessation of respiration was used as the end point in these 
33 
experiments. 
Indomethacin (INDO) Treatment 
Indomethacin (Sigma) was freshly prepared by dissolving 
in 0.1 M sodium phosphate buffer. A dose of 10 mg/kg was 
administered by intraperitoneal injection and an equivalent 
volume of vehicle was administered to controls. These 
injections were made 30 minutes prior to feces injection. 
Materials 
The following were purchased from commercial sources: 
[5,6,8,9,11,12,14,15- 3 H] TXB 2 (60-70 ci/mM) and 
[5,8,9,11,12,14,15-3H]-6-keto-PGFla(10~ Ci/mM) from New 
England Nuclear, Boston, Massi organic solvents from Burdick 
and Jackson Laboratocies, Muskegon, Michi silicic acid, 
Biasil A200-400 mesh from Bio-Rad Laboratories, Richmond, 
California; char-coal and dextran from Schwartz/Mann Div. 
Becton-Dickinson, orangeburg, N.Y. Authentic prostaglandins 
were the generous gift of Dr. J. pike, Upjohn. 
Statistical Analysis 
Unpaired Student's t-test was used to determine 
differences in plasma iTXB 2 , plasma i6-keto-PGF 1a., and FDP 
between control and experimental groups. A paired t-test 
was used for platelet counts. 
employed for mortality studies. 
The Chi-square test was 
Confidence limits were 




iTXB2 and i6-keto-PGF1aLevels 
Untreated Shocked Rats 
Fecal peritonitis was associated with increased plasma 
levels of both iTXB 2 and i6-keto-PGF h . Both increased 
within 15 minutes and remained elevated throughout the 
course of the disease. plasma levels of iTXB 2 (Fig. 3) 
rapidly increased froin non-detectable (ND<200 pg/ml) to 
1,066 + 194 pg/ml (N=14) 1 hour after feces injection. 
iTXB 2 then increased to 1,695 .:!: 218 pg/ml (N=16) at 4 hours 
and remained unchanged through 6 hours. plasma i6-keto-PGF1a 
(Fig. 4) increased from ND to 3,777 + 414 pg/ml (N=16) at 1 
hour. Four hours after administration of feces, i6-keto-
PGF1a levels rose to 6,945 + 732 pg/ml (N=16) then continued 
to rise to 9,465 + 792 pg/ml (N=7) at 6 hours. The 6 hour 
time point is approximately 2 hours prior to death. 
Effects oi Essential Fat!Y Acid (EFA) geficiency or 
Indomethacin (INDO) Pretreatment 
Either EFA deficiency or INDO pretreatment 
significantly decreased (P<0.01) the elevations in plasma 
levels of both iTXB 2 and i6-keto-PGF1a associated with fecal 
peritonitis (Fig. 5). iTXB2 levels were non-detectable 
«200 pg/ml) at 1 hour and only slightly elevated in EFA 
deficient rats (234 + 14 pg/ml) at 4 hours. plasma i6-keto-
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Figure 3. Plasma iTxB2 levels during septic shock. Bars 
represent ± SEM. N ranged from 4 to 13 for 






























Figure 4. Plasma i6-keto-PGFla (6-KETO) levels during 
septic shock. Bars represent ~ SEM.. N ranged 



















Figure 5. Comparative plasma iTxB2 and i6-keto-PGFla 
(6-KETO) levels during septic shock in untreated 
control, essential fatty acid deficient (EFAD), 
and indomethacin (INDO) treated rats at 1 and 4 
hours after ip fecal suspension. Bars represent 
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PGF1a was also non-detectable except for a slight increase 
in EFA deficient rats (451 + 198 pg/ml) at 4 hours. 
Consumptive Coagulopathy 
Thrombocytopenia 
Platelet counts were taken at zero time on all r-ats and 
counts at each time point were converted to a percentage of 
the zero time value, each cat thus serving as its own 
control. The zero time platelet count was 1.20 + 0.02 x 10 6 
platelets/mm 3 (N=80). EFA deficient rats had a 
significantly higher zero time platelet count (2.0 + 0.09 x 
10 6 platelets/mm 3 ; N=10; P<0.01). The indomethacin 
pretreated group platelet counts at zero time were not 
d iff ere n t fro In con t r 0 1 • Platelet counts did not 
significantly fall until 6 hours after administration of 
fecal suspension (Table II). Thrombocytopenia was present 
at 6 hours and was significantly improved by indomethacin. 
Fibrin Degradation Products (FDP) 
In untreated shocked rats, FDP were significantly 
elevated (P<0.01) 6 hours after feces injection (Table III). 
At 6 hours FDP were 18 + 3 ug/ml. This elevation was 
significantly reduced by either EFA deficiency (7 + 2 ~g/ml; 
P<0.05) or INDO pretreatment (4 + 0.7 1l9/ml; P(0.01). 
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TABLE II 
Platelet Counts in Essential Fatty Acid Deficient (EFAD) 
and Indomethacin (INDO) Treated Rats During Sept1c Shock. 
Time After Feces 
Group 15 Minutes 1 Hour 4 Hours 6 Hours 
Septic 99 ± 8 ( 3) 96 * 15 ( 3) 104 ± 16 (3) 55 ± 8 (4) 
EFAD --------- ---------- ------------ 60 ± 6 (4) 
INDO --------- ---------- ------------ 80 ± 3 (4)* 
Platelet counts are expressed as percent of pre-feces values. 
Indomethacin (10 mg/kg) was given ip 30 minutes nrior to feces. 
Numbers represent Mean ± SEH (N), *P<O.OS comoared to Sentic. 
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Table III 
Fibrin Degradation Products (FDP) in Essential Fatty 
Acid Deficient (EFAD) and Indomethacin (INDO) Treated 
Rats During Septic Shock. 
Group 15 Minutes 1 Hour 4 Hours 6 Hours 
2.13 ± 0.5 ( 3 ) 3.2 ± 1.6 (3) 5.3 ± 1.1 (3) 18 ± 3 (4 ) 
-- ..... -----~----- ----.- ..... - .......... __ ... - .-... ... - ................ ------- 7 + 2 (4)* 
Septic 
EFAD 
INDO - .......... - ........... -- ..... ~--- --..-------~----- -.------------ 4 ± 0.7 (4)** 
FOP expressed in ug/ml. Non-septic levels were 1.3 ± 0.4 ~q/ml. 
Indomethacin (10 mg/kg) was given ip 30 minutes prior to feces. 
Numbers represent r1ean ± SEM (N); *P <0 .. 05; **P:: 0.01 compared to septic. 
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Effects of Essential Fatty Acid Deficiency or Indomethacin 
on Survival 
Mean survival time of untreated shocked rats was 8.6 + 
0.2· hours (Fig. 2). Either EFA deficiency or INDO 
pretreatment (10 mg/kg; ip), significantly enhanced 
survival. Survival time for EFA deficient rats was 1".2 + 
0.4 hours (P<0.01). INDO pretreated rats also showed an 
increase survival time of 13.3 + 0.6 hours (P<0.01). At 
both 9 and 12 hours (Fig. 6) there was a statistically 
significant improvement in survival (P<0.01) for both groups 
compared to controls. INDO pretreatment was also associated 
with significantly enhanced survival (P<0.05) at 18 hours 
(Fig. 6) compared to EFA deficient and control rats. 
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Figure 6. Comparative percent survival during septic shock 
of untreated control (CNTL) 1 essential fatty acid 
deficient (EFAD) and indomethacin (INDO) treated 
rats at 6,9,12, and 18 hours after ip fecal 
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Fecal peritonitis is an established model system used 
in various studies of responses to septic insults. Artz et 
ale (1962) established fecal implantation as a method to 
test irrigation and antibiotic therapy procedures. Later 
studies demonstrated that mortality varied with inoculum 
size (Nichols et al., 1978); and, described two stages, an 
early acute peritonitis stage and a later abscess stage in 
survivors (Weinstein et al., 1974). Fecal peritonitis has 
also been used to describe metabolic and hemodynamic 
responses to intraabdominal sepsis. A study by Yates et ale 
(1980) showed the absence of a direct correlation between 
circulating endotoxin and these parameters, thus emphasizing 
that septic shock and endotoxic shock are not identical. 
In this study, dose dependent response and the absence 
of variability among fecal suspension preparations indicate 
the reproducibility of peritonitis produced by instillation 
of feces. Bacteriologic studies confirmed a consistent 
Gram-negative septicemia (Pseudornona~ Eutida). The dose 
used in these experiments produced a highly reproducible 
mean survival time well within the acute septic peritonitis 
phase (Fig. 2). 
previous studies have reported elevations of 
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arachidonic acid metabolites in endotoxic shock (Anderson ~ 
a1., 1975; Cook et a1., 1980; Fletcher et a1., 1980b). The 
ben~ficial effects of cyclooxygenase inhibitors (aspirin, 
indomethacin, ibuprofen) and essential fatty acid 
deficiency, imply the pathogenic involvement of these 
metabolites in endotoxic shock tCOOK et al., 1980; Cook et 
!!.!.. , 1 9 8 1 ; Hal u s h k a e t a .!.. , 1 9 8 1 ) • Stu die sus i n 9 
thromboxane synthetase inhibitors (imidazole, 7-(1-
imidazolyl) heptanoic acid) support a potential role for 
TXA 2 in the pathogenesis of endotoxic shock in the rat (Cook 
et a1., 1980; Wise.!:J: al., 1981). Study of the involvement 
of arachidonic acid metabolites in 
more limited. Dalldorf et al. 
septic shock has been 
(1978) reported the 
protective effect of aspirin in experimental meningococcal 
septicemia but no correlation was made with arachidonic acid 
metabolism. Most recently, Short ~ ale (1981) reported 
that indomethacin improved survival in Gram-negative sepsis 
from both fecal peritonitis and E. coli induced intra-
abdominal sepsis. However, no studies have been performed 
on the production of TXA 2 and PGI 2 in a model of septic 
shock. 
A major difference between sepsis and bolus endotoxin 
centers around the time course of the insult. Intra-
abdominal sepsis results in a continued assault on the 
organism that includes progressive release of endotoxin. 
This time course difference is reflected in the production 
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of TXA2 and PGI2 in these two systems. 
revealed extended synthesis of both 
The present studies 
products in feca 1 
peritonitis shock in contrast to transient production in 
bolus endotoxic shock. Significant elevations in the plasma 
levels of the metabolites of TXA2 and PGI 2 were observed 
throughout the time course of fecal peritonitis (Fig. 3 and 
Fig. 4). plasma levels of iTXB 2 rose during the first 15 
minutes, again at 2 hours and then remained unchanged. In 
contrast to iTxB2' the PGI 2 metabolite, i6-keto-PGF 1a ' 
rea c he dIe vel sal m 0 S ton e f u 1 lor de r 0 f In a 9 nit u d e 9 rea t e r 
and continued to rise sharply from 3 hours through the 
remainder of the study. 
PGI2 has been shown to be beneficial when infused early 
in endotoxic and traumatic shock (Lefer et al., 1979; Lefer 
et al., 1980). However, the results of these studies do not 
exclude the possibility that excess production of PGI2 in 
the terminal phase of sepsis may be deleterious. Continued 
pro due t ion 0 f PC; I 2 i [) the t e r tn ina 1. P has e 0 f f e cal 
peritonitis shock is interesting because it suggests a 
potentially pathogenic role. It is tempting to speculate 
t hat the inc rea sin 9 s Y nth e sis 0 f P G I 2 may rO e d i ate 
counterproductive vasodilation in the terminal hypotensive 
phase of circulatory shock. This is not to say that PGI2 
may not have beneficial effects during shock. Rather, a 
proper balance of this and other vasoactive substances may 
be the key factor. The potential cole of TXA2/PGI2 as a 
balanced control mechanism in thrombus and hemostatic plug 
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formation has been well described (Moncada ~ al., 1979). 
The precise role of this system in circulatory shock is not 
cl~ar; however, the observations in this and other studies 
suggest that reduced production of arachidonic acid 
metabolites is beneficial in the generalized shock state. 
In this regard, further investigation into the balance of 
TXA 2 /PGI 2 synthesis during shock should provide important 
information. 
Another significant finding of this study was that EFA 
deficiency and INDO treatment were effective in reducing the 
synthesis of both TXA2 and PGI 2 that is associated with 
fecal peritonitis (Fig. 5). Reduction of TXA 2 and PGI 2 
production in EFA deficient rats and INDO treated rats is 
similar to previous results with endotoxic shock (Cook et 
~l. , 1 9 7 9 i W i see t ~l., 1 9 8 0 ) • T his red u c t ion 0 f 
arachidonic acid metabolism is associated with partial 
alleviation of consumptive coagulopathy and enhanced 
survival. The development of consumptive coagulopathy 
during fecal peritonitis was documented in this study in 
terms of thrombocytopenia (Table II) and increased fibrin 
degradation products (Table III). Coagulopathy was 
attenuated in either EFA deficient or INDO treated rats. 
Severity of thrombocytopenia was not altered by EFA 
deficiency despite a reduction in FDP. Fibrin degradation 
products an indirect measure of disseminated intravascular 
coagulation, were decreased by either experimental 
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procedure. Reduced TXA2 production in these experimental 
procedures is thought to mediate these protective effects. 
In addition, both EFA deficiency and INDO pretreatment 
produced highly significant increases in survival (Fig. 6). 
The efficacy of these distinctly different experimental 
procedures in the treatment of septic shock is particularly 
noteworthy. EFA deficiency depletes arachidonic acid, the 
precursor of the prostaglandins and thromboxanes. INDO 
inhibits cyclooxygenase, the enzyme that converts 
araChidonic acid to the endoperoxide intermediates for the 
prostaglandins and thromboxanes. Thus, the same end result 
is attained by completely different mechanisms. Actions of 
INDO that are not mediated through inhibition of arachidonic 
acid metabolism would not be present in EFA deficient 
animals. This result strongly implicates arachidonic acid 
metabolites as functional mediators of the pathophysiology 
of septic shock. 
In summary, the initial phase of this project has shown 
that fecal peritonitis induces increased production of TXA 2 
and PGI2 and has identified the alteration of arachidonic 
acid metabolism as part of the sequelae of septic shock. 
Furthermore, decreased production of these metabolites 
during fecal peritonitis in EFA deficient and INDO treated 
rats was associated with significantly enhanced survival 
time. This enhanced survival was also correlated with less 
severe coagu!opathies. The next phase will further 
delineate the roles of these substances in shock by 
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selective inhibition of TxA 2 production. 
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Chapter III 
STUDIES ON THE ROLE OF TI!ROMBOXAr~ES AND PROSTACYCLI!~ 
DURIt-JG SHOCK INDUCED BY INTRAABDOMlr~AL SEPSIS 
INTRODUCTION 
Previous studies have shown that thromboxane A2 (TXA 2 ), 
a vasoconstrictor and platelet pro-aggregator, and 
prostacyclin (PGI 2 ), a vasodilator and platelet anti-
aggregator, are elevated in the plasma of rats during 
end 0 to x i c s hoc k ( Coo k e't a 1 • , 1 9 8 0 i H a r r i set a 1 • , 1 9 8 " ; 
Halushka et ~l., 1981). Bacterial endotoxin is thought to 
initiate many of the pathologic events of septic shock 
(Wardle, 1979); and, in this regard, TXA2 and PGI 2 are 
considered to be deleterious and beneficial mediators 
respectively (Lefer, 1979; Cook et al., 1980; Lefer et al., -- ---
1980; Demling et al., 1981; Wise et al., 1981). Studies 
using thromboxane synthetase inhibitors have supported a 
deleterious role for TXA 2 in endotoxic shock (Cook et al., 
1980; Wise et al., 1980b). 
The initial phase of this project has shown that these 
arachidonic acid metabolites are also elevated during shock 
resulting from fecal peritonitis. Furthermore, decreased 
production of these metabolites in essential fatty acid 
deficient and indomethacin pretreated rats was associated 
with less severe coagulopathies and enhanced survival during 
intraabdominal sepsis (see Chapter II). A major difference 
between fecal peritonitis induced sepsis and bolus endotoxin 
administration centers around the time course of the insult. 
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Increased production of TxA2 and PGI 2 appear to temporally 
parallel the insult. This correlation is consistent with 
the .concept that these substances may be integral mediators 
of the host response to these pathologic stimuli. 
To evaluate the potential role of TXA2 and PGI 2 during 
fecal peritonitis, a model of septic shock, the second phase 
of this project investigated the effects of the thromboxane 
synthetase inhibitor, 7(1-imidazolyl). heptanoic acid (7-
IHA). The response to pretreatment with 7-IHA was compared 
and contrasted to the response to pretreatment with 
indomethacin and essential fatty acid deficiency (Chapter 
I I ) • Ibuprofen, a cyclooxygenase inhibitor, was also 
administered as an analogue of indomethacin treatment. The 
following parameters were measured in control and treated 
rats after induction of shock by intraperitoneal injection 
of feces: 1) plasma levels of iTXB 2 (the stable metabolite 
of TXA2) i 2) plasma levels of i6-keto-PGF 1 a. (the stable 
metabolite of PGI 2 ); 3) survival time; 4) severity of 
thrombocytopenia; and 5) serum levels of fibrin degradation 
products. 
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MATERIALS AND METHODS 
Fecal peritonitis was induced in female Long-Evans rats 
using the same procedures described in Chapter II. 
Radioimmunoassay of immunoreactive (i) TXB 2 and 6-keto-PGF1a 
, assessment of consumptive coagulopathy, and survival time 
were also performed as previously described. The following 
additional materials and methods were utilized in this phase 
of the project. 
Non-Septic peritonitis 
Fecal suspension prepared as described above was 
autoclaved (270 C for 30 minutes; Steril Quik Model 704-
9000) and injected into the peritoneal cavity of rats to 
produce a non-septic peritonitis. 
7-{l-imidazolyl) Heptanoic Acid (7-IHA) 
7-IHA was synthesized using a previously described 
method (Burch et al., 1980). 7-IHA was diluted in 0.1 M 
sodium-phosphate buffer (pH 8.0) prior to administration. A 
dosage of 60 mg/kg was injected ip in a volume of 0.2 
ml/100g body weight 30 minutes prior to intraperitoneal 
fecal suspension. An equivalent volume of vehicle was 
administered to controls. 
Ibuprofen 
Ibuprofen (Motrin; The Upjohn Company, Kalamazoo, MI), 
was diluted in 0.1 M sodium-phosphate buffer. A dosage of 5 
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mg/kg was administered ip in a volume of 0.2 ml/100 9 body 
weight 30 minutes prior to intraperitoneal fecal suspension. 




plasma iTXB2 and i6-keto-PGF1a Levels 
Untreated Shocked Rats 
As seen in Chapter II, fecal peritonitis was associated 
with increased plasma levels of both iTXB 2 and i6-keto-PGF la 
(Fig. 7). Both increased within 15 minutes after 
instillation of fecal suspension and remained elevated 
throughout the period of observation. Plasma levels of 
iTXB2 rapidly increased from non-detectable (ND<200 pg/ml) 
to 1,067 + 194 pg/ml (N=14) 1 hour after injection of feces, 
rose slightly by 4 hours, and then remained essentially 
unchanged through 6 hours. Plasma i6 -k eto-PGF1 Ct increased 
from ND to 3,777 + 414 pg/ml (N=16) by 1 hour and remained 
unchanged until four hours after administration of feces. 
At 4 hours, plasma i6-keto-PGF1a levels rose to 6,945 + 792 
pg/ml (N=16) then continued to rise to 9,465 + 792 pg/ml 
(N=7) at 6 hours. The 6 hour time point is approximately 2 
hours prior to death for untreated rats. 
Non-septic peritonitis 
In contrast to septic peritonitis, non-septic 
peritonitis was produced by injection of sterile feces. 
Sterile feces was used to ensure that a septic phenomenon 
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Figure 7. Plasma iTxB2 and i6-keto-PGFla (6-KETO) levels 
during septic shock. Fecal peritonitis was 
produced at time zero by ip injection of fecal 
suspension (0.75 mg dry weight/kg body weight). 
Bars represent ± SEM. N ranged from 4 to 16 
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was being studied as opposed to a response to endotoxin 
present in the fecal suspension (See "Survival" below). 
This also allowed for determination of the level of TXA2 and 
PGI 2 production during non-lethal peritonitis. Non-septic 
peritonitis was associated with elevated plasma levels of 
iTXB 2 and i6-keto-PGFla (Fig. 8). plasma iTXB 2 levels were 
440 + 26 pg/ml (N=5) at 1 hour and 580 + 58 pg/ml (N=5) at 4 
hours after feces injection. i6-keto-PGF1a levels were 1844 
+ 515 pg/ml (N=5) and 1406 + 473 pg/ml (N=5) at 1 and 4 
hours respectively. All of these values are significantly 
lower (P<0.01) than the corresponding values in shocked 
rats. 
Effects of 7-(1-imidazolyl) Heptanoic Acid (7-IHA) 
The thromboxane synthetase inhibitor, 7-IHA, inhibited 
the elevation of plasma iTXB2 that is associated with fecal 
peritonitis (Fig. 8). Plasma iTXB 2 was non-detectable «200 
pg/ml; N=9) 1 hour after injection of fecal suspension and 
was only 508 + 56 pg/ml (N=6) at 4 hours. These values both 
represent significant reductions (P<0.01) cOlupared to 
untreated shocked rats. In contrast, i6-keto-PGF1Cl plasma 
levels at 1 hour were 5,185 + 467 pg/ml (N=9), which was 
significantly greater (P<0.05) than levels in shocked 
untreated cats. The i6-keto-PGF1a levels at 4 hours (55~3 + 
665 pg/ml; N=6) were not different from untreated rats. 
Reduced plasma levels of iTXB 2 in 7-IHA treated shocked rats 
were less than (at 1 hour; P<0.01) or not different from (at 
4 hours) iTXB2 levels associated with non-lethal, non septic 
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Figure 8. Compartive plasma iTxB2 and i6-keto-PGFla (6-KETO 
levels during septic shock in untreated control, 
7 (I-imidazolyl) heptanoic acid (7-IHA) treated 
and non-septic peritonitis (AUTO) rats. 7-IHA 
(60 mg/kg) was administered ip 30 minutes prior 
to fecal suspension. Non-septic peritonitis was 
induced by ip injection of autoclaved fecal 
suspension. Bars represent ± SEM (N=5-l6); 
*P<O.Ol compared to control; **P<O.Ol compared 
to either control or 7-IHA. 
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peritonitis induced by injection of sterile feces. However, 
plasma i6-keto-PGF1a was significantly higher (P(0.01) in 7-
IHA. t~eated rats compared to non-septic peritonitis rats at 
both 1 and 4 hours after fecal suspension injection. 
Ibuprofen 
Pretreatment with ibuprofen (5 mg/kg,ip) significantly 
reduced (P<0.05) the elevations of plasma iTXB 2 and i6-keto-
PGFla. that is associated with fecal peritonnitis (Table IV). 
At 4 hours after injection of fecal suspension, iTXB 2 levels 
were 729 + 99 pg/ml (N=6) and i6-keto-PGF 1a levels were 
1,327 + 251 pg/ml (N=6). 
Survival 
Mean survival time of untreated shocked rats was 8.6 + 
0.2 hours (N=5) with zero survival by 14 hours after 
injection of fecal suspension. Injection of sterile fecal 
suspension was associated with 100% long-term survival (>48 
hours; N=12). This confirms that active sepsis was an 
integral part of this septic shock model. Endotoxin 
released by bacterial lysis in the sterile fecal suspension 
was not sufficient to produce endotoxic shock. 
7-(1-imidazolyl) Heptanoic Acid (7-IHA) 
There was no alteration of survival in 7-IHA treated 
shocked rats. Mean survival time of 7-IHA treated shocked 
rats was 8.1 + 0.5 hours (N=10) with zero survival by 12 
hours after injection of fecal suspension. At 6, 9, 12, and 
18 hours, there was no significant difference in percent 
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Table IV 
Plasma iTxB 2 and i6-keto-PGF1a in Ibuprofen Treated 
Rats During Septic Shock 
iTXB 2 i6-keto-PGF la. 
Group (pg/rnl) (pg/m1) 
Control 1,681 ± 248 (13) 6,945 ± 732 ( 16) 
IBUP 729 :!: 99 (6)* 1,327 ::i; 251 (6)** 
All values are 4 hours after ip fecal suspension 
and are expressed as Mean ± SEM (N). 
**P<O.Ol compared to controls. 
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*P<O.05j 
survival of 7-IHA treated compared to untreated shocked rats 
(Fig. 9). 
Ibuprofen 
Pretreatment with ibuprofen, a cyclo-oxygenase 
i n h i bit 0 r , s i 9 n i fie ant 1 yen han c e d 5 U r v i val t i nl e fro m 8 .6 + 
0.2 hours to 12.5 + 1.1 hours (N=11; P(0.01). At 9, 12, and 
18 hours there was a statistically significant improvement 
(P<0.05) in percent survival cornpared to untreated controls 
or 7-IHA treated rats (Fig. 9). 
Consumptive Coagulopathy 
Thrombocytopenia 
Platelet counts were taken at zero time on all rats and 
counts at each time point were converted to a percentage of 
the zero time value, each rat thus serving as its own 
control. The zero time platelet count was 1.20 + 0.02 x 10 6 
platelets/mm3 (N=80). 7-IHA pretreated platelet counts at 
zero time were not different from control. Thrombocytopenia 
was present at 6 hours after injecti.on of the fecal 
suspension and was not significantly improved by 7-IHA 
pretreated (Table V). 
Fibrin Degradation Products (FDP) 
In untreated shocked rats, FDP were significantly 
elevated (P<0.0l) 6 hours after feces injection (Table II). 
This elevation was significantly reduced (P<0.05) from 18 + 
3 119 / m lin u n t rea ted s hoc ked rat s to 7 + 2 11 9 / m lin 7 - I H A 
pretreated rats (Table V). 
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Figure 9. Comparative percent survival during septic shock 
of untreated control (CNTL), 7 (I-imidazolyl) 
heptanoic acid (7-IHA) treated and ibuprofen 
(IBUP) treated rats. 7-IHA (60 mg/kg) and IBUP 
(S mg/kg) were administered ip 30 minutes prior 
to feces. N=lS (CNTL and 7-IAH) and 11 (IBUP)~ 
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Consumptive Coagulation Parameters in 7-IHA 






55 ± 8 (6) 
64 ± 5 (4) 
FDP 
(ug/ml) 
18 ± 3 (6) 
7 ± 2 (4)* 
Platelet counts are expressed as percent of 
pre-feces value. Fibrin degradation products 
(FOP) in normal rats were 1.3 ± 0.4 Ug/ml. 
7-IHA (60 mg/kg) was given ip 30 minutes prior 
to feces. Data is expressed as Mean ± SEM (N): 
*P<O.Ol compared to Septic. 
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DISCUSSION 
In previous studies, plasma iTXB 2 and i6-keto-PGF 1a 
increased within 30 minutes after intraperitoneal injection 
of fecal suspension in rats and remained elevated until 
death. Essential fatty acid deficiency depletes arachidonic 
acid and indomethacin inhibits fatty acid cyclooxygenase 
which converts arachidonic acid to endoperoxide precursors 
of TXA 2 and PGI 2 • Both of these experimental procedures 
have been shown to decrease plasma iTXB2 and i6-keto-PGF1a 
and enhance survival during fecal peritonitis (See Chapter 
II). In this study, pretreatment with ibuprofen, another 
fatty acid cyclooxygenase inhibitor (McIntyre, 1977) was 
comparable to essential fatty acid deficiency and 
indomethacin pretreatment in that it reduced both iTXB 2 and 
i6-keto- PGF lct to levels no 
peritonitis and significantly 
greater .than non-septic 
enhanced survival. This 
provides further evidence that arachidonic acid metabolites 
playa role in the pathophysiology of septic peritonitis. 
However, it remains uncertain as to which metabolites are 
contributing to which pathophysiologic sequelae. 
7-IHA inhibits thromboxane synthetase but not fatty 
acid cyclooxygenase (Yoshimoto, 1978). Pretreatrnent with 
this inhibitor prevented the elevation in plasma iTXB 2 
levels during fecal peritonitis and caused apparent shunting 
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of arachidonic acid metabolism to PGI2 early in the course 
of the shock syndrome. Plasma iTXB 2 levels in 7-IHA treated 
rats were at or below those levels observed in non-lethal 
sterile fecal peritonitis throughout the observation period. 
However, elevations of plasma i6-keto-PGF b were greater in 
7-IHA treated than in untreated rats at 1 hour after feces, 
and 7-IHA did not improve survival during fecal peritonitis. 
7-IHA pretreatment was associated with decreased formation 
of fibrin degradation products. Essential fatty acid 
deficiency and indomethacin pretreatment have been 
previously shown to reduce fibrin degradation products 
during fecal peritonitis (See Chapter II). The identifiable 
common feature of all of these experimental procedures is 
the reduction of TXA 2 production. collectively, these 
observations support the involvement of thromboxane in 
producing disseminated intravascular coagulation during 
fecal peritonitis. 
Lack of protective efficacy of 7-IHA in septic shock 
induced by fecal peritonitis was unanticipated since 
thromboxane synthetase inhibition with 7-IHA or irnidazole 
has been shown to be protective in endotoxic shock (Cook et 
al., 1980; Wise et al., 1980b; Wise et al., 1981). This 
discrepancy may result in part from the greater severity of 
the septic insult or from the differences in the time course 
of TXA 2 and PGI 2 production in fecal peritonitis compared to 
bolus endotoxin induced shOCk. In fecal peritonitis both 
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iTXB2 and i6-keto-PGF 1ex, levels are elevated throughout the 
course of the disease (See Chapter II), whereas in endotoxic 
shock, iTXB 2 production is early and short lived while i6-
keto-PGF1a levels rise later and are sustained over several 
hours (Harris et al., 1980; Cook et al., 1981b). There is 
also a difference in the hemodynamic response of septic 
versus endotoxic shock. In septic shock, there is usually a 
normal or high cardiac output and normal or low total 
peripheral resistance. In experimental endotoxic shock, 
cardiac output is usually reduced and total peripheral 
resistance is high. The explanation for this difference 
appears to reside in the actions of the Joicrovasculature. 
Observations of arteriovenous oxygen differences and oxygen 
uptake suggest that blood flow shunting occurs in septic 
shock (Lillehei, 1972; Weil et al., 1972; Weil et al., 
1979). The explanation for this type of microvascular 
shunting in septic and not other forms of shock is unclear, 
but it seems to be related to the inflammatory response 
induced by bacteria (Lillehei, 1972). TXA2 and PGI 2 are 
among the vasoactive substances produced during the 
inflamInatory response (Moncada ~ al., 1979; Weksler et al., 
1980; Cook et al., 1981; Feuerstein ~ al., 1981) and TXA 2 
is known to be a potent vasoconstrictor while PGI2 is a 
potent vasodilator (Moncada et a.!.., 1979). These 
observations are consistent with the notion that the 
vasoactive properties of these two arachidonic acid 
metabolites may mediate alterations in the microcirculation 
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such as stagnant anoxia and arteriovenous shunting. The 
differences in TXA 2 and PGI 2 production observed between 
inf~ammatory septic peritonitis and bolus endotoxin could 
then correspond to the differences in microvascular dynamics 
of septic versus endotoxic shock. 
The involvement of PGI 2 in shock induced by intra-
abdominal sepsis is of particular interest. PGI 2 , as 
measured by its stable metabolite, i6-keto-PGF 1a. I has been 
shown to be elevated during endotoxin induced hypotension 
( B u 1 t, 1 9 7 8 ; H a r r i s e t ~!., 1 9 8 0 i W i see t a .!.., 1 9 8 0 ) • 
Harris et ale (1980) showed a positive telnporal correlation 
between systemic arterial pressure decline and increasing 
i6-keto-PGF 1a levels during endotoxic shock in baboons. 
Results of the initial phase of this project have also shown 
very high elevations of i6-keto-PGF1a during the terminal, 
hypotensive phase of acute intraabdorninal sepsis (see 
Chapter II). These implications for PGI2 involvement in the 
vasodepression observed during shock are further supported 
by the effectiveness of indomethacin in preventing the 
decrease in systemic arterial pressure (Harris et al., 
1980), decreasing the plasma i6-keto-PGF1a elevations (see 
Chapter II) and enhancing survival (Cook et al., 1980; 
Fletcher et al., 1980b; and See Chapter II). 
In the present studies inhibition of thromboxane 
synthetase by 7-IHA during fecal peritonitis led to apparent 
shunting of arachidonic acid to prostacyclin synthetase 
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since i6-keto-PGF1a plasma levels were significantly higher 
than untreated, septic animals at 1 hour after feces 
injection. At 4 hours after injection of fecal suspension, 
plasma i6-keto-PGF 10'. in 7-IHA treated rats was highly 
elevated, but not different from untreated controls. These 
observations coupled with the lack of protective efficacy of 
7-IHA, are consistent with the notion that early elevations 
of endogenous PGI 2 are not beneficial in terms of survival 
and may actually be detrimental during fecal peritonitis in 
the rat. They do support the idea that PGI 2 may be 
responsible for counterproductive vasodepression in various 
forms of circulatory shock. On the other hand, PGI 2 has 
been shown to be beneficial when infused early in endotoxic 
(Lefer et al., 1980), traumatic (Lefer et al., 1979), and 
hemorrhagic shock (Seelig, 1981). Thus, at the present 
time, it appears that early pharmacologic administration of 
PGI2 may be beneficial in some forms of shock, whereas 
endogenous release may be associated with ineffective 
perfusion and terminal hypotension. 
In summary, the second phase of this project has shown 
that decreased production of TXA2 and PGI 2 by ibuprofen is 
associated with enhanced survival while a selective decrease 
of TXA2 production by 7-IHA is not protective in terms of 
survival during fecal peritonitis. However, selective 
decrease of TxA2 production is associated with less severe 
coagulopathies. The response of i6-keto-PGF 1a to 7-IHA 
treatment provides further evidence that PGI 2 may be a 
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mediator of the terminal hypotension observed in circulatory 
shock. These observations are not in agreement with the 
preyailing view that TXA2 is deleterious and PGI 2 is 
beneficial in shock states. The finding that selective 
inhibition of TXA 2 production lessened the severity of 
coagulopathies but did not improve survival tends to limit 
its role in the pathophysiology of septic shock. 
Conversely, the marked increase in production of PGI 2 in the 
terminal phase of septic shock imply a possibly pathogenic 
role in terms of the basic failure of the shock syndrome-
loss of effective perfusion. Whether PGI2 plays a specific 
role in microvascular arteriovenous shunting and/or becomes 
involved in general vasodepression is unknown at the present 
time. 
In any event, these two arachidonic acid metabolites 
have been implicated in the pathophysiology of septic shock. 
Reduction of arachidonic acid metabolism by prostaglandin 
synthetase inhibition (indomethacin, ibuprofen) or by 
essential fatty acid deficiency is associated with reduced 
coagulopathies and increased survival time. The possibility 
that these treatments could enhance standard antibiotic 
administration and the effect of the antibiotic, gentamicin, 
on TXA2 and PGI 2 production were considered in the final 
phase of this project. 
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CHAPTER IV 
SYNERGISM BET~mEN GENTM4ICIN AND INDO~mTHACIN OR 
ESSENTIAL FATTY ACID DEFICIENCY IN THE TREAT~mNT OF 
SEPTIC SHOCK: EFFECTS ON THE PRODUCTION OF 
THROMBOXANE A2 AND PROSTACYCLIN 
INTRODUCTION 
During shock induced in rats by intraabdominal sepsis, 
circulating levels of iTxB 2 and i6-keto-PGF p the stable 
metabolites of thromboxane (Tx) A2 , and prostacyclin (PGI 2 ) 
respectively, are elevated as described in Chapter II. TXA2 
is a vasoconstrictor and platelet pro-aggregator while PGI2 
is a vasodilator and ant-i-aggregator (Moncada et al., 1979). 
These opposing actions in the vascular system suggest a 
possible role in the pulmonary hypertension, systemic 
hypotension and disseminated intravascular coagulation seen 
during shock (Lefer, 1979). Essential fatty acid (EFA) 
deficiency depletes arachidonic acid and indomethacin (INDO) 
inhibits fatty acid cyclooxygenase which converts 
arachidonic acid to endoperoxide precursors of TXA 2 and 
PGI2. These distinctly different experimental procedures 
decrease plasma levels of both iTXB 2 and i6-keto-PGF p and 
are associated with less severe coagulopathies and enhanced 
survival during fecal peritonitis (See Chapter II). 
The need to define treatment procedures to effectively 
deal with pathophysiologic events of shock that often 
accompany sepsis is well recognized (Ballis, 1979; preston, 
1979; Wardle, 1979; Duff, 1980; Kreger, 1980). The primary 
intervention in the treatment of sepsis is administration of 
antibiotics (Preston, 1979; Wardle, 1979; Duff, 1980). 
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Gentamicin (GENT) has a broad spectrum of bactericidal 
activity against enteric micro-organisms and is currently 
the.aminoglycoside most widely used for the treatment of 
severe Gram-negative infections. Therefore, the objective 
of this phase of the project was to investigate the possible 
synergism between an antibiotic, gentamicin, and 
experimental procedures that reduce arachidonic acid 
metabolism in the treatment of fecal peritonitis in the rat. 
Either INDO pretreatment or EFA deficiency was combined with 
administration of GENT. The following parameters were 
measured in treated and untreated rats challenged with 
intraperitoneal injections of feces: 1) survival time; 2) 
plasma iTXB2 (the stable metabolite of TXA 2 ); 3) plasma 16-
keto-PGF1a (the stable metabolite of PGI 2h 4) severity of 
thrombocytopenia; and 5) fibrin degradation products. The 
influence of GENT on TXA 2 and PGI 2 production was also 
evaluated in cultured rat peritoneal macrophages and in rats 
during shock induced by iv Salmonella enteritidis endotoxin. 
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MATERIALS AND METHODS 
Fecal peritonitis was induced in female Long-Evans rats 
using the same procedures as described in Chapter II. 
Radioimmunoassay of immunoreactive (i) TXB 2 and 6-keto-PGF1a, 
assessment of consumptive coagulopathy and survival time 
were also performed as previously described. The following 
additional materials and methods were utilized in this phase 




(8 igma) was 
A dose 
diluted in 0.1 M 
of 2.5 rng/kg was 
administered by intraperitoneal injection and an equivalent 
volume of vehicle was administered to controls. These 
injections were made 30 minutes prior to feces injection. 
For GENT + INDO treatment, the same proced~re was used with 
GENT injection followed immediately by INDO injection at a 
different site on the abdominal wall. GENT serum levels 
were measured by the Clinical Chemistry Department (Medical 
University of South Carolina) using a radioimmunoassay kit 
(American Diagnostics, Newport Beach, California). 
Macrophage Cultures 
Male Long-Evans rats 9-10 weeks old, were used as a 
source of peritoneal leukocytes in these studies. Resident 
peritoneal leukocytes were obtained by peritoneal lavage 
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with 10 ml of sterile RPM! 1640 (Microbiological 
Associates). Adherent peritoneal cells were obtained by 
incubating 4 ml of 1 x 10 6 cells/ml in 60 x 15 mm plastic 
culture dishes (Falcon) in RPMI 1640 for 2 hours at 37 C in 
humidified air and 5% CO 2 - The plates were then washed 3 
times with 3 ml of RPM! 1640 medium to remove non-adherent 
cells. RPMI medium (4 rol) was added to the plates and the 
plates were then incubated for intervals of up to 24 hours. 
Viability was >95% for cells cultured up to 24 hours as 
determined by trypan blue exclusion. On the basis of 
differential staining and positive histochemical stains for 
esterase with the substrate alpha napthol butyrate (Lawrence 
et al., 1980) the adherent cells were 90% macrophages. The 
remaining cells were lymphocytes whereas PMN's comprised 
less than 1%. 
Salmonella enteritidis endotoxin (Boivin preparation 
#684081 from Difco, Control Laboratories, Detroit, Michigan) 
was added to the culture medium at a concentration of 50 
g/ml. Gentamicin sulphate (Sigma) as diluted . 1 n RPM I 
medium and this solution was added to the experimental 
culture medium in a final concentration of 10 ~g/ml. 
Supernatants from the cultures were collected at designated 
time intervals and passed through 0.22 ~m filters (Millipore 
Corp). Radio immunoassay of iTXB 2 and i6-keto-PGF 1Cl in 
unextracted culture supernatants were performed as 
previously described (Cook et al., 1981c). 
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Endotoxic Shock 
Male Long-Evans rats, 175-220 grams, from the same 
breeding colony were used for this part of the study. 
Endotoxic shock was induced by administering a single 
intravenous (iv) dose of Salmonella enteritidis endotoxin 
(15 mg/kg) to rats lightly anesthetized with ether. The 
endotoxin was a Boivin preparation 1684081 from Difco. 
Materials 
The following were purchased from commercial sources: 
[S,6,8,9,11,12,14,15- 3 H] TXB 2 (60-70 Ci/mM) and 
[5,8,9,11,12,14,15- 3 H]-6-keto-PGF l a. (100 Ci/mM) from New 
England Nuclear, Boston, Mass; organic solvents from Burdick 
and Jackson Laboratories, Muskegon,. Mich.; silicic acid, 
Biosi01 A200-400 mesh from Bio-Rad Laboratories, Richmond, 
California; charcoal and dextran from Schwartz/Mann Div. 
Becton-Dickinson, Orangeburg, N.Y. 
Statistical Analysis 
Unpaired Student's t-test was used to determine 
differences in plasma iTXB 2 , plasma i6-keto-PGF1a , and FDP 
between control and experimental groups. A paired t-test 
was used for platelet counts. The Chi-square test was 
employed for mortality studies. Confidence limits were 




Gentamicin Serum Levels 
The serum levels of gentamicin were measured in shocked 
rats to confirm that effective levels were reached during 
the period of the study (Table VI). GENT serum levels 
peaked at 1 hour (3.8+0.46 llg/ml) and declined from 
1.03+0.18 J.,9/ml at 4 hours to non-detectable «0.2 llg/ml) at 
12 hours. These levels were also measured in GENT + INDO 
treated rats to determine if INDO increased circulating 
levels of GENT as a possible explanation for synergistic 
benefit. This, however, was not the case since there was no 
significant difference between the levels in each group. 
Survival 
The mean survival times of untreated, INDO treated, 
GENT treated, and GENT+INDO treated rats are shown in Table 
VII. The survival time of the GENT+INDO group was 
significantly greater than the GENT group (P<0.01), which in 
turn, was significantly greater than the INDO pretreated 
group (P(0.01). Either GENT+INDO or GENT+EFA deficiency 
produced significantly greater survival than GENT alone 
(P<0.01) 24 hours after intraperitoneal injection of fecal 
suspension (Fig. 10). Survival was similarly enhanced at 
both 30 and 36 hours after induction of fecal peritonitis 
(P<0.01). Long term survival was considered as greater than 
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Table VI 
Gentamicin Serum Levels During Fecal Peritonitis 
Group 
GENT 




3.8 ± 0.5 (3) 
4.2 + 0.5 (3) 
4 Hours 
1.0 ± 0.2 (3) 




Serum levels of gentamicin (GENT) were measured by radio-
immunoassay with a non-detectable level (ND) of 0.2 ugjml. 
Gentamicin (GENT) (2.5 mg/kg) was administered in 30 minutes 
prior to feces. 
Indomethacin (INDO) (10 mg/kg) was administered ip 30 minutes 
prior to feces. 
Numbers represent l:lean :!: SEM (N). There were no significant 






Survival Time, Platelet Counts, and Fibrin Degradation 
Products During Fecal Peritonitis 
Survival Time Platelets FOP 
(Hours) (%) (~ g/rn1) 
6 Hours 12 Hours 6 Hours 
Untreated B.6 ± 0.2(50) 55 ± 8(4) - ... __ .......... -- 18 ± 3.2(4) 
INDO 13.3 ± 0.6(21)** 80 ± 2(4)* ---------- 4 ± O.7(4)** 
GENT 23.8 ± 2.6(16}** 61 ± 8(4) 50 ± 9(4) 11 ± 1.4(4) 
GENT + INDO 41.4 ± 1.8(17)**,a 64 ± 11(4) 41 ± 8(4) 4 + O.9(4)**,a 
Platelet counts are expressed as percent of pre-feces value. 
Fibrin degradation products (FDP) in non-septic controls were 1.3 ± 0.4 ~g/ml. 
Indomethacin (INDO) (10 mg/kg) was given ip 30 minutes prior to feces. 
Gentamicin (G~NT) (2.5 mg/kg) was given ip 30 minutes prior to feces. 
12 Hours 
..... - ...... ---_ ........ -
-- .... - .. - ... -----
11 ± 1.4(4) 
6 ± O.7(4)a 
Numbers represent Hean :io SEM on; *P<O.05; **P<O .. Ol compared to Septic; ap<O.Ol compared to GENT .. 
Figure 10. Comparative percent survival during septic shock 
of gentamicin treated (G), gentamicin treated plus 
indomethacin pretreatment (G+I) and gentamicin 
treated plus essential fatty acid deficient (G+E) 
rats. The time points shown are 24, 30, and 36 
hours after intraperitoneal injection of fecal 
suspension. Long term survival (>48 hours) is 
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48 hours. GENT+INDO and GENT+EFA deficiency were the only 
treatments to provide this amount of protection - 35% (N=17) 
and 30% (N=7) long term survival respectively (P<0.01 
compared to GENT alone). 
Plasma iTXB2 and i6-keto-PGFla Levels 
Fecal peritonitis was associated with increased plasma 
levels of both iTXB 2 and i6-keto-PGF 1a. (see Chapter II). 
Both increased within 15 minutes after instillation of fecal 
suspension and remained elevated throughout the period of 
observation. plasma levels of iTXB 2 rapidly increased from 
non-detectable «200 pg/ml) to 1,066+194 pg/ml (N=14) 1 hour 
after feces injection. Plasma iTXB 2 then increased to 
1,695+218 pg/ml (N=15) at 4 hours and remained unchanged 
through 6 hours. Plasma i6-keto-PGF1 a. increased from non-
detectable to 3,777+414 pg/ml (N=16) at 1 hour. Four hours 
after administration of feces, i6-keto-PGF l a. levels rose to 
6,945+732 pg/ml (N=16) then continued to rise to 9,465+792 
pg/ml (N=7) at 6 hours. The 6 hour time point is 
approximately 2 hours prior to death for untreated rats. 
Either EFA deficiency or INDO pretreatment 
Significantly decreased (P<0.01) the elevations in plasma 
levels of both iTXB 2 and i6-keto-PGF 1a associated with 
fecal peritonitis. iTxB 2 levels were non-detectable «200 
pg/ml) at 1 hour and only slightly elevated in EFA deficient 
rats (234+14 pg/ml) at 4 hours. Plasma i6-keto-PGFla was 
also non-detectable except for a slight increase in EFA 
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deficient rats (451+198 pg/ml) at 4 hours. 
GENT pretreatment did not alter iTXB 2 plasma levels 
compared to untreated controls (CNTL) at 1, 4, or 6 hours 
after feces injection (Fig. 11). plasma iTXB 2 was 672+241 
pg/rnl at 12 hours in GENT treated rats. CNTL rats did not 
survive 12 hours for comparison. GENT pretreatment 
significantly decreased i6-keto-PGF la plasma levels at 4 
hours (3,443+156 pg/ml; P<0.QJ1) and 6 hours (3096+1174 
pg/mlj P<0.01) after feces injection compared to CNTL (Fig. 
12). Plasma i6-keto-PGF la levels at 12 hours were 
2,673+1023 pg/ml. Combined administration of GENT and INDO 
resulted in significant reduction (P<0.01) of both iTXB 2 and 
i6-keto-PGF l a. plasma levels to non-detectable «200 pg/ml) 
at 1,4,,6, and 12 hours after instillation of fecal 
suspension (Fig. 12). 
Consumptive Coagulopathy 
The assessment of thrombocytopenia via platelet counts 
and of disseminated intravascular coagulation via fibrin 
degradation products (FDP) for untreated, INDO treated, GENT 
treated, and GENT+INDO treated rats at 6 houes after feces 
are presented in Table VII. Values at 12 hours are not 
available for untreated or INDO groups since most of these 
animals did not survive this long. Values are presented for 
GENT and GENT+INDO treated rats at 12 hours after induction 
of fecal peritonitis. These parameters show improvement 
only in groups treated with INDO or GENT + INDO. In INDO 
treated rats platelets increased from 55 + 8% to 80+3% 
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Figure 11. Comparative plasma iTxB2 levels during septic 
shock of untreated controls (CNTL), gentamicin 
treated (G) and gentamicin plus indomethacin 
treated (G+I) rats at I, 4, and 12 hours after 
fecal suspension injection. aValue for CNTL 
are not available since most untreated rats die 
prior to 12 hours. Bars represent ± SEM. N 
ranged from 5 to 16 for individual groups; *P<O.Ol 
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Figure 12. Comparative plasma i6-keto-PGFla (6-KETO) levels 
during septic shock of untreated control (CNTL), 
gentamicin treated (G) and gentamicin plus 
indomethacin (G+I) treated rats at 1, 4, 6, and 
12 hours after fecal suspension injection. 
aValues for CNTL are unavailable since most 
untreated animals die prior to 12 hours. Bars 
represent ± SEM; N ranged from 5 to 16 for 
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(P(0.05) at 6 hours. FDP decreased from 18+3.2 119/ml in 
un t rea ted s e p tic rat s to 4 + 0 • 7 l-lg / m 1 i n IN DOt rea ted 
(P(0 .• 01) and to 4+0.9 llg/ml (P(0.01) in GENT+INDO treated 
rats at 6 hours. FDP were significantly decreased from 
11 + 1 .4 119 / m 1 
(P(0.01) and 
in the GENT 
6 + 0 • 7 119 / m 1 
treated group to 4+0.9 
(P(0.eJl) at 6 and 12 
respectively in the combined GENT+INDO treated group. 
Effect of Gentamicin ~ Macrophage Cultures 
l-lg/ml 
hours 
Gentamicin (10 l19/ml) did not significantly alter the 
production of iTXB 2 or i6-keto-PGF la by control or endotoxin 
stimulated rat peritoneal macrophages in 5 hour cultures. 
Unstimulated cells produced iTXB 2 levels of 69.5+3.4 ng/ml/5 
hours and the addition of GENT did not alter this level 
(54.2+5.4 ng/ml/5 hours). Macrophages stimulated with 
endotoxin produced iTxB 2 levels of 129+11.9 ng/ml/5 hours 
and this again was not altered by GENT (129+3.1 ng/ml/5 
hours). Unstimulated cells produced i6-keto-PGFla levels of 
21.3+3.4 ng/ml/5 hours and this also was not altered by GENT 
(17.7+1.4 ng/ml/5 hours). Macrophages stimulated with 
endotoxin produced i6-keto-PGFla levels of 30.5+2.4 ng/ml/5 
hours. Again, ther-e was no significant alteration by GENT 
(37.5+2.4 ng/ml/5 hours). 
Effect of Gentamicin on Endotoxic Shock 
As shown in Figures 13 and 14 at 30 minutes after the 
induction of endotoxic shock, GENT pretreatment 
significantly reduced iTXB? plasma levels from 1,420+199 - -
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Figure 13. Comparative plasma iTxB2 levels during endotoxic 
shock of untreated, endotoxin (LPS) shocked rats 
and gentamicin pretreated, endotoxin (LPS/GENT) 
shocked rats at 30 minutes and 4 hours after iv 
administration of Salmonella enteritidis 
endotoxin (15 mg/kg). Plasma iTxB2 levels in 
un shocked rats are non-detectable «200 pg/ml). 
Bars represent ± SEM7 N is in parentheses above 
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Figure 14. Comparative plasma i6-keto-PGFla levels during 
endotoxic shock of untreated, endotoxin (LPS) 
shocked rats and gentamicin pretreated, endotoxin 
(LPS/GENT) shocked rats at 30 minutes and 4 hours 
after iv administration of Salmonella enteritidis 
endotoxin (15 mg/kg). Plasma i6-keto-PGFla 
levels in unshocked rats are non-detectable (<200 
pg/ml). Bars represent ± SEMi N is in parentheses 
above the corresponding bar. *P<O.05: **P<O.OOl 
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pg/ml (N=8) to 901+131 pg/ml (N=12j P<0.05) and 
significantly reduced i6-keto-PGF 1a plasma levels froIn 
871+140 pg/ml (N=8) to 505+76 pg/ml (1~=12; P<0.05). At 4 
h 0 u or s aft ere n dot 0 x in, i T x B 2 pIa sma 1 eve lsi n G EN T 
pretreated rats (662+120 pg/ml; N=12) were not different 
from untreated controls (915+141 pg/ml; N=8). However, GENT 
pretreatment significantly decreased plasma i6-keto-PGF l a at 




In the initial phase of this project it was shown that 
production of TXA2 and PGI 2 was markedly elevated throughout 
the course of fecal peritonitis in the rat. In essential 
fatty acid (EFA) deficient rats and in rats pretreated with 
the cyclooxygenase inhibitors, indomethacin (INDO) or 
ibuprofen, decreased production of these metabolites was 
associated with less severe coagulopathies and enhanced 
survival (see Chapters II and III). The key question of the 
present investigation was whether the decrease of 
arachidonic acid metabolism could be used as an adjunct to 
antibiotic treatment of sepsis. 
Gentamicin (GENT) was chosen for these studies because 
of its extensive clinical use (Appel, 1973), and because it 
has been shown to effectively reduce.the early death 
observed in rats challenged with a fecal inoculum 
(Weinstein, 1975). In confirmation of this previous 
observation, results of this study demonstrated that GENT 
alone was very effective in prolonging survival in a fecal 
peritonitis model. However, it did not increase long term 
survival (>48 hours), nor did it significantly lessen the 
severity of disseminated coagulopathies. Rats treated with 
GENT alone exhibited plasma levels of i6-keto-PGF 1a that 
were significantly decreased, but iTXB 2 levels were not 
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diffe~ent from untreated shocked controls. TXB2 is the 
stable metabolite of TxA 2t a vasoconstrictor and platelet 
agg~egator. TXA2 has been implicated in the coagulopathies 
associated with endotoxic (Cook et al.,s 1980; Wise, 1980b; 
Wise et al., 1981) and septic (see Chapters II and III) 
shock. The results of this study are consistent with this 
concept in that treatment with GENT alone did not decrease 
iTXB 2 levels and was not associated with improved parameters 
of coagu!opathy. Addition of INDO to GENT pretreatment 
inhibited the production of iTXB 2 and was associated with 
less severe coagulopathies as measured by fibrin degradation 
products. PGI 2 has the opposing actions of vasodilation and 
inhibition of platelet aggregation. Some investigators have 
proposed this as a protective substance and early infusion 
has been shown to be protective in hemorrhagic (Seelig, 
1981), traumatic (Lefer et al., 1979) and endotoxic (Lefer 
et al., 1980) shock. On the other hand, studies have shown 
a temporal correlation of i6-keto-PGF 1a production with 
terminal hypotension in endotoxic shock (Harris et al., 
1980). In addition, very high levels of i6-keto-PGF1a have 
been observed during the terminal phase of fecal peritonitis 
and the lowering of plasma iG-keto-PGF1a. has consistently 
been associated with improved survival from fecal 
peritonitis in the earlier phases of this project. The 
present findings are consistent with the latter viewpoint 
since GENT alone enhanced survival and decreased plasma 
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i6-keto-PGF l a. • Addition of INDO to GENT pretreatment 
further decreased plasma i6-keto-PGF1a and further enhanced 
survival. Indeed, the combination of pretreatment with 
~ 
antibiotic (GENT) and cyclooxygenase inhibitor (INDO) 
produced 35% survival at 48 hours after injection of fecal 
suspension. Furthermore, the combination of GENT and EFA 
deficiency was associated with 30% survival at 48 hours. 
These findings are in agreement with the results of Short et 
al. (1981) who observed increased survival in E. coli 
intraabdominal sepsis treated with GENT and INDO combined. 
However, fecal peritonitis, used in the present study, was a 
much more stringent test system with no long term survival 
in untreated, INDO treated, EFA deficient, or GENT treated 
rats. 
The synergistic effects of these distinctly different 
ex per i In e n tal pro c e d u res, IN D 0 0 C E FAd e fie i en c y, com bin e d 
with the administration of an antibiotic to produce long 
term survival is particularly noteworthy. INDO inhibits 
fatty acid cyclooxygenase, the enzyme that converts 
arachidonic acid to the endoperoxide intermediates for the 
prostaglandins (including PGI 2 ) and thromboxanes. EFA 
deficiency depletes arachidonic acid, the initial precursor 
in the prostaglandin and thromboxane cascade. Therefore, 
the same end result is obtained by entirely different 
mechanisms. Actions of INDO that are not mediated through 
inhibition of arachidonic acid metabolism would not be 
present in EFA deficient animals. These results strongly 
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suggest that decreased arachidonic acid metabolism may 
provide the basis for a procedure that is synergistic with 
ant~biotic administration in the treatment of septic shock. 
The physiologic basis for the synergistic protective 
action of INDO or EFA deficiency and GENT pretreatment is 
not known. One possibility may be that a reduction of 
arachidonic acid metabolism aids in effectively distributing 
GENT to peripheral sites through the actions of the 
TXA2/PGI2 system. This would be consistent with the finding 
that suppression of arachidonic acid metabolism lessens the 
severity of coagulopathy, presumably by decreasing TXA2 
production, thereby improving tissue perfusion. It is 
interesting to note that a similar mechanism has been 
proposed for 9 lucocortico ids dur ing shock (H inshaw, 1980). 
Another possible explanation may be that INDO or EFA 
deficiency lessens the effect of endotoxin released by the 
bactericidal actions of GENT and thus exerts protection as 
demonstrated in endotoxic shock (Cook et al., 1980; Wise et 
al., 1981). 
Another interesting aspect of this study was the 
finding that GENT decreased the production of i6-keto-PGF1u 
during fecal peritonitis. The actions of GENT, an 
aminoglycoside, are not completely understood (Sande, 1980). 
The initial findings of the present study suggested that 
gentamicin may selectively reduce PGI 2 metabolism. This 
action could be either a direct effect on prostacyclin 
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synthetase or an indirect effect via its bactericidal 
activities reducing the severity of the insult. 
Gentamicin was added to peritoneal macrophage cultures 
in order to test for a direct effect on either thromboxane 
or prostacyc 1 in synthetase. The finding of no direct 
inhibition of iTXB 2 or i6-keto-PGF 1a production in either 
stimulated (endotoxin) or unstimulated macrophages argues 
against a direct inhibitory mechanism on either of these 
enzymes. 
To further investigate the effects of GENT on 
arachidonic acid metabolism during shock, rats were 
pretreated with GENT and then given iv bolus endotoxin to 
produce endotoxic shock. The bactericidal effects of GENT 
should be of no benefit in terms of the direct actions of 
endotoxin. Coupled with the observation of no direct 
inhibition the finding that GENT significantly reduced the 
production of both iTXB 2 and i6-keto-PGF 1U during in vivo 
endotoxin administration implies that th.is system is more 
complex than direct cellular stimulation by endotoxin. 
There is, perhaps, a cascade of events that are precipitated 
by the action of endotoxin on host cells that ends in a 
massive production of TXA2 early and PGI 2 later in the 
C 0 U r s e 0 fen dot 0 x i c s hoc k • V ill a ~E. a ..!. • ( 1 9 8 1) h a v e 
reported that there was not direct interaction between 
endotoxin and endothelial cell production of prostacyclin in 
vitro but stimulation was observed in vivo thus implying a 
complex interplay between endotoxin and vessel walls. In 
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another study (Feuerstein et al., 1981), incubation of lung 
strips with endotoxin in vitro failed to stimulate 
pro~taglandin release in contrast to the effect of endotoxin 
in vivo. These authors suggest that prostaglandin 
production by endotoxin stimulation in vivo is mediated by 
factors produced by immunoreactive cells. Rampart et ale 
(1981) have observed a decreased endotoxin stimulated 
production of i6-keto-PGF 1a after complement depletion in 
rabbits. This implies that an activated component of the 
complement cascade may mediate PGI 2 release in endotoxic 
shock. The effects of gentamicin on these proposed 
mediators is unknown. It is conceivable that endotoxin 
could induce TXA2 and PG1 2 production directly in 
Inacrophages but a cascading of this activity to other 
tissues would be blocked by inhibition of the synthesis of a 
mediating factor(s) in vivo by gentamicin. In addition, the 
reduction of both iTXB2 and i6-keto-PGF1a plasma levels in 
endotoxic shock as opposed to selective decrease of i6-keto-
PGFla in fecal peritonitis may reside in the differences in 
production of these substances already observed between 
these two models (I,ll). Further investigation into the 
effects of GENT on TXA 2 and PGI 2 production should reveal 
important information about gentamicin's actions and the 
pathophysiology of shock. 
In summary, combination of gentamicin administration 
and either indomethacin pretreatment or essential fatty acid 
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deficiency synergistically improved long term survival from 
fecal peritonitis. Gentamicin alone did not alter TXA 2 
production, but gentamicin plus indomethacin decreased TXA2 
. 
production and was associated with enhanced survival time. 
Gentamicin did not affect in vitro production of iTXB2 or 
i6-keto-PGF 1a by peritoneal macrophages but reduced 
production of both of these arachidonic acid metabolites 
during in vivo endotoxic shock. These observations support 
a complex interaction of bacteria, endotoxin, host tissues, 





· The results obtained in this project have all supported 
the hypothesis that the arachidonic acid metabolites TXA 2 
and PGI2 are functionally involved in the pathophysiology of 
circulatory shock induced by septic peritonitis. These 
studies have also supported the concept of a deleterious 
role for TXA 2 in consumptive coagulopathies associated with 
septic shock. However, the findings were not compatible 
with the description of PGI 2 as a strictly beneficial 
mediator during septic shock. 
Summary of Findings 
The first phase of the project, documented increased 
plasma levels of TXA 2 and PGI 2 metabolism as part of the 
sequence of septic shock. RadioilnInunoassay of stable 
metabolites, TXB 2 and 6-keto-PGF1a , for determining TXA 2 and 
PGI2 levels is a widely used and accepted technique 
(Granstrom, 1980). Indomethacin was used to eliminate 
collection artifact_ Therefore, iTXB2 and i6-keto-PGF 1a 
plasma levels were considered to be indicative of TXA2 and 
PGI 2 plasma levels. The plasma levels of a substance 
reflect the balance between the relative rates of synthesis 
and degradation or clearance; therefore, the increased 
plasma levels reported here do not by themselves correspond 
to increased production of TXA 2 or PGI 2 - Flynn et ale 
(1977) have determined that increased production and not 
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decreased degradation was responsible for the elevated 
plasma levels of PGE 2 and PGF 2a during endotoxin 
administration. Elevated plasma TXB2 and 6-keto-PGF1U have 
been shown to decrease rapidly (on the order of minutes to 
hours) during endotoxic shock implying that degradation 
proceeds in the abscence of overriding production (Harris ~ 
al., 1980). In the present septic shock model, plasma 
levels tended to plateau instead of decrease implying only 
that production equaled degradation. However, the sharp 
increase of plasma levels immediately after injection of 
fecal suspension certainly implies increased production. 
During the terminal stages of shock iTXB 2 production versus 
degradation is equivocal since plasma levels are plateaued. 
However, TXB 2 and 6-keto-PGF 1a. are chemically related 
molecules and are degraded by similar mechanisms involving 
the same types of catabolic enzymes (Moncada e.!. al., 1979; 
Rosenkranz et al., 1980). Therefore, the concomitant steep 
rise in 6-keto-PGFla again implies increased production. 
Since the periods of increasing plasma levels and the 
relative levels of TXA2 versus PGI2 production were of major 
significance in the present study, this type of analysis is 
sufficient. Future studies, however, may require label and 
washout measurements to establish synthesis and degradation 
rates. The increased production of both TXA 2 and PGI 2 
during the initial stage of septic shock, and the late 
continuation of increased production of PGI 2 relative to 
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TxA2 were, then, the prominent features of fecal peritonitis 
and ace in contrast to results reported using endotoxic 
shock. EFA-deficiency (depletion of arachidonic acid) or 
INDO pretreatment (cyclooxygenase inhibition) decreased the 
production of these metabolites during fecal peritonitis 
induced shock and was associated with enhanced survival and 
less severe coagulopathies. 
The second phase of the project further substantiated 
phase one by demonstrating the protective efficacy of 
ibuprofen (a cyclooxygenase inhibitor). In addition, 
selective inhibition of TXA2 production by 7-IHA was 
associated with less severe coagulopathies, but did not 
enhance survival. These observations suggested that both 
similarities (e.g., TXA2 effect on coagulopathies), and 
differences (e.g., TXA 2 effect on survival) are present when 
comparing a septic fecal peritonitis response to a bolus 
endotoxin response. The response of PGI 2 metabolite 
production after 7-IHA pretreatment was consistent with the 
concept that prostacyclin is a mediator of altered vascular 
flow and pressure associated with circulatory shock. 
The final phase demonstrated that combination of 
gentamicin administration and either indomethacin 
pretreatment or essential fatty acid deficiency 
synergistically improved long term survival from severe 
fecal peritonitis. During this study, the effects of 
gentamicin on TXA 2 and PGI 2 production have revealed some 
intriguing possibilities. GENT alone did not alter TXA 2 
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production and was not associated with significant reduction 
of fibrin degradation products. GENT alone selectively 
dec~eased PGI2 production during fecal peritonitis and was 
associated with enhanced survival time. Cultured peritoneal 
macrophages were not affected by gentamicin in terms of 
unstimulated or endotoxin stimulated iTXB 2 or i6-keto-PGF 1a 
production. GENT pretreatment significantly reduced 
production of both of these arachidonic acid metabolites 
early and i6-keto-PGF l a late in endotoxin induced shock in 
ra ts. These findings imply a complex interaction of 
bacterial endotoxin, host tissues, and gentamicin in the 
regulation of arachidonic acid metabolism and support 
reports of the involvement of ill-defined mediating factors 
in the production of TXA 2 and PGI 2 • A hypothetical model 
system that incorporates all of these present observations 
should provide a framework for evaluating the requirements 
of future studies. 
A Hypothetical Model for the Involvement of Thromboxane and 
prostacyclin in Septic Shock. 
The current view of how thromboxane and prostacyclin 
may be involved in septic shock is depicted in Figure 15. 
This general concept includes cellular sources of TXA2 and 
PGI 2• These substances work in a counterbalance mechanism 
to control relative constriction versus dilation and 
platelet aggregability in the vascular system. In septic 
shock this balance is upset resulting in loss of effective 
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Figure 15. Current view of how thromboxane and prostacyclin 
may be involved in sentic shock. 
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perfusion. The resulting toxic metabolic products of both 
host and bacterial cells provide a positive feedback 
mechanism. 
As with any biological system, new information usually 
reveals increased complexity. Utilizing the data obtained 
in the present study, Figure 16 diagramatically represents 
one possible description of the involvement of TXA 2 and PGI 2 
in septic shock as a cascade of events reSUlting in positive 
feedback circuits. Initiation at the top of the figure is 
the result of bacterial infection which produces numerous 
general and specific inflammatory stimuli and direct tissue 
damage. Lipopolysaccharide or endotoxin is but one of these 
initiative stimuli. The composite reaction to this 
stimulation is the release of numerous biologically active 
substances including local production of the potent 
vasoactive arachidonic acid metabolites TXA 2 and PGI 2 • 
Immunoreactive cells have been shown to produce both of 
these products while platelets produce TXA2 and endothelial 
cells produce PGI 2 in the vasculature of the infected area. 
Other cells could also be involved in the production of 
arachidonic acid metabolites. 
Regardless of the source, TXA2 and PGI 2 interact to 
balance the vasomotor tone and platelet aggregation state in 
the inflamed area. The extent of this inflammatory tissue 
involvement will depend on the size and nature of the septic 
insult, but the occurrence of a shock syndrome is the result 
of a rapidly spreading systemic involvement. It is proposed 
79 
Figure 16. Proposed model for cascade effect of thromboxane 
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here that this systemic involvement is mediated at least in 
part by TXA 2 and PGI 2 - These substances may travel in the 
vas~ular system to produce direct effects on platelets, 
endothelial cells, and possibly other cell types_ However, 
there appear to be circulatory mediators of an undefined 
nature that may lead to a cascade effect on arachidonic acid 
metabolites_ The evidence foe the presence of these 
mediating factors was discussed in Chapter III and included 
the blocking effect of gentamicin at the points indicated on 
Figure 16_ Gentamicin inhibited PGI 2 production during both 
fecal peritonitis and endotoxic shock while only during 
endotoxic shock did this antibiotic reduce TxA 2 production. 
This difference may be caused by the additional stimuli 
present in fecal peritonitis producing a direct systemic 
effect via circulating TxA2 or another substance not blocked 
by gentamicin. TXA 2 is known to have positive stimulatory 
effects on platelet aggregation and release of more TXA2. 
Endothelial cells respond to this stimulation by producing 
PGI 2 - TXA 2 thus provides a source of positive feedback 
circuit in this system. The actions of PGI 2 in this regard 
are not well defined, but this substance is known to inhibit 
TXA 2 release by platelets and counteract the aggregating and 
vasoconstrictor influences of TXA2- Therefore, on the 
systemiC level, these two vasoactive substances are involved 
as a balanced mechanism to control the flow of blood in the 
viscera. It is at the level of the microvasculature that 
the systemic imbalance of these substances could produce the 
pathophysiologic events seen in the shock syndrome. An 
initial imbalance of TXA2 would produce vasoconstriction of 
arterioles and venules and promote platelet aggregation and 
stasis. This situation could correspond to the initial 
state of ischemic anoxia associated with septic shock. A 
later increase of PGI 2 production would be expected to 
eventually override the constrictor effects of TXA 21 perhaps 
more selectively in the arterioles. This could produce 
stagnant anoxia and pooling which is associated with the 
later stages of septic shock. The markedly high production 
of PGI 2 observed in the fecal peritonitis model used in 
these studies could also account for a dilation that 
produces arteriovenous shunting through preferred route 
capillaries and the terminal hypotension seen in septic 
peritonitis. Such selective localized actions of PGI 2 
versus TXA2 in the microcirculation have not been directly 
observed. Howeve r, 
(1981) demonstrates 
a recent publication by Hales et al. 
that the interplay of TXA2 and PGI 2 
levels after low-dose endotoxin could substantially account 
for the observed changes in pulmonary vascular tone. These 
mechanisms could then produce the tissue anoxia and 
production of toxic metabolic products. These products 
could produce positive feedback at any of the three levels 
labelled on Figure 16, resulting in further increases of 
systemic TXA 2 and PGI2. 
It is important to keep in mind that this system is not 
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acting in isolation. The background upon which the 
arachidonic acid metabolites act includes large amounts of 
neu~ohumoral, hormonal, activated complement and kinin 
mediators, none of which are considered to be 
inconsequential. 'However, the potency, placement, and 
observed production of the vasoactive arachidonic acid 
metabolites during shock imply a commanding role in 
pathophysiologic sequelae and certain aspects of the 
proposed model system highlight several areas for further 
research. 
Directions for Future Research 
~---------- ---- ------- ---------
At level 1 on Figure 16, the involvement of the 
mononuclear phagocyte system (also called the 
reticuloendothelial system) and other arulS of the immune 
response are intimately tied to arachidonic acid metabolism. 
'rhe exact involvement of this system in both the local and 
systemic response to sepsis leading to shock is unclear. 
Study of this level is particularly important since this 
level appears to contain the initiating events of septic and 
endotoxic shock 
Level 2 on the diagram contains the most recently 
described and least understood interactions. Identification 
of the undefined mediating factors may result from 
experiments designed to dissect the actions of gentamicin 
that fall outside of its bactericidal activity. This may 
also lead to better understanding of the other 
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am inog lycos ide antibiot ics. Prel im ina ry exper imen ts would 
include investigation of other antibiotics and gentamicin's 
effects on complement activation. 
~ Level 3 studies could include investigation of the 
effects of TXA 2 and PGI 2 on specific portions of the 
microcirculation in addition to further correlation of these 
substances to systemic hemodynamics. The interaction of 
PGI2 with various cell types and the description of its 
feedback properties are also important. PGI 2 infusion and 
selective inhibition of PGI2 production ace of highest 
priority to further support the concepts derived from the 
present investigation. Identification of the substances 
involved in positive feedback loops is also a primary 
concern. 
It is interesting to note that the major features of 
the proposed model system include mediating factors and 
positive feedback. These are reminiscent of the humoral 
factors and "vicious circle" described by Cannon, Fraser, 
Cowell and others in 1918. These superb investigators 
labelled the crucial elements with only the most basic 
observations of shock victims. Since that time many 
observations have led to the description of many complex 
events associated with shock, but the crucial events have 
yet to be identified. Future studies to define these events 
must certainly consider the involvement of arachidonic acid 
metabolites. 
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